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Abstract
Obstructive sleep apnea syndrome (OSAS) is a serious medical condition that 
occurs during sleep and consists of episodes of complete (respiratory pauses) or partial 
obstruction (hypoventilation) of the upper airway. Approximately 80% of persons 
diagnosed with OSAS are prescribed nasal Continuous Positive Airway Pressure 
(CPAP) treatment, which has proven to be the treatment of choice for OSAS. However, 
noncompliance with CPAP treatment in OSAS patients is a widely recognized problem, 
and many persons refuse CPAP as a treatment option or fail to use it reliably. 
Investigations o f CPAP use in OSAS patients have generally found that nightly use 
averages less than five hours. Few interventions have been scientifically evaluated for 
improving CPAP compliance. The current study evaluated a method of introducing 
OSAS patients to CPAP prior to the administering CPAP titration in the laboratory. 
Participants in the treatment groups underwent a 30-minute CPAP habituation trial, with 
a range of pressures, prior to the polysomnography with CPAP. It was hypothesized 
that the participants who experienced CPAP habituation would have better sleep quality 
during CPAP, would be more likely to accept CPAP, and would use CPAP more on a 
nightly basis than control participants who experienced the usual laboratory procedures 
for introducing CPAP (CPAP education) to OSAS patients. There were no statistically 
significant differences for any of the dependent variables between participants who 
experienced CPAP habituation and participants who experienced CPAP education.
Men were found to use CPAP 1.61 hours more on a nightly basis than women (p = .03). 
This difference is most likely attributable to severity, as men were observed to have an 
A+HI that was twice the observed A+HI of women participants. Overall, CPAP
v
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acceptance and compliance for the complete sample was comparable to what has been 
reported in the CPAP treatment literature.
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Introduction
Obstructive sleep apnea syndrome (OSAS) is a serious medical condition that 
occurs during sleep and consists of episodes of complete or partial obstruction of the 
upper airway, which coincides with excessive daytime sleepiness (EDS; Orr, 1997). It 
is the most common organic disorder of EDS that is diagnosed in sleep disorders clinics 
and is the most common of the sleep apnea syndromes (Partinen, 1994). Furthermore, 
OSAS is the most severe and most common form of sleep apnea/hypopnea syndrome 
(SAHS) and can have dire health consequences if not properly managed. Central sleep 
apnea is also a serious sleep-related breathing disorder during which repeated 
respiratory pauses occur during sleep, presumably due to a loss of respiratory effort 
(White, 1994). Unfortunately, no completely effective treatment for central sleep apnea 
has been developed, and the focus of the present review with be on OSAS and its 
treatment. Cross-sectional studies indicate that the minimum prevalence of SAHS is at 
least 1% (Partinen, 1994). However, the prevalence of SAHS increases with age, and a 
recent study of persons aged 30 to 60 years found rates of sleep apnea of 2% for women 
and 4% for men (Young et al., 1993). Additionally, these same investigators found that 
4% of women and 9% of men aged SO to 60 had more than 1S apneas per hour asleep 
(Young et al., 1993). In persons aged 65 and older, as many as 25% may experience 
more than 5 apneas per hour asleep (Kripke & Ancoli-Israel, 1983). Of those diagnosed 
with OSAS, it is estimated that 80% are prescribed nasal Continuous Positive Airway 
Pressure (CPAP) treatment. Nasal CPAP has proved to be the treatment o f choice for 
patients with OSAS due to its great effectiveness in eliminating apnea and normalizing 
the sleep architecture (i.e., the composition of sleep; Sullivan & Grunstein, 1994).
1
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In OSAS, episodes of complete obstruction of the upper airway are referred to as 
apneas while episodes of partial obstruction are referred to as hypopneas. An episode 
of complete (i.e., apnea) or partial airway obstruction (i.e., hypopnea) must last for a 
minimum of 10 seconds and must occur during sleep to be scored as a respiratory event. 
However, sleep apneas and hypopneas typically last between 20 and 40 seconds, and 
severe events can last up to 120 seconds. These sleep-related respiratory events are 
usually accompanied by a drop in available blood oxygen (Sa02) and often by a central 
nervous system (CNS) arousal response and an autonomic nervous system (ANS) 
arousal response. Such activation of the CNS results in transient arousals from sleep, 
and if great enough, complete awakenings. Transient arousals from sleep take the form 
of bursts of alpha waves (8-11 cycles per second) lasting between 3 and 14 seconds, 
which degrade the overall quality of sleep causing it to be light and discontinuous 
(American Sleep Disorders Association [ASDA], 1992). If transient arousals occur at 
high rates, the sleep architecture can be markedly altered, with reductions of stages 3 
and 4 non-rapid eye movement (NREM) sleep, referred to collectively as slow wave 
sleep (SWS) and a reduction of rapid eye movement (REM) sleep. Large numbers of 
transient arousals will also increase stage 1 NREM sleep, which is regarded as 
light/transitional sleep. Blood oxyhemoglobin desaturation usually occurs during or 
shortly after sleep apneas and hypopneas, with oxygen desaturation below 85% being 
considered severe, although desaturations can be as low as 50%.
One important measure of the severity of OSAS is the number of sleep-related 
respiratory events per hour asleep, which is given in the form of the Apnea + Hypopnea 
Index (A+HI). The diagnostic criterion for the frequency of sleep-related respiratory 
events in SAHS is a minimum of 5 events per hour asleep; however, significant
2
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pathology is not thought to occur until there are 10 or more events per hour asleep 
(Guilleminault, 1994). Patients suffering from clinically significant symptoms and 
sequelae o f OSAS typically will have 20 or more episodes of apnea/hypopnea per hour 
asleep. People suffering from severe OSAS may have apneas with arousal as often as 
twice per minute, or 120 arousals from sleep per hour (Roth, Roehrs, & Zorick, 1982). 
According to the authors of the International Classification of Sleep Disorders-Revised, 
in addition to the criterion of an A+HI of at least S per hour asleep, the respiratory 
obstructions must be accompanied by one or more of the following: frequent arousals 
from sleep that are associated with airway obstruction, bradytachycardia, and arterial 
oxygen desaturation that is associated with the sleep-related respiratory events the 
(ASDA, 1997). Severity of OSAS is categorized as mild, moderate, or severe according 
to the A+HI, the level of daytime sleepiness, the severity of oxygen desaturation, the 
presence of cardiac arrhythmias, and the level of impairment in daytime functioning 
(ASDA, 1997). In general, the daytime consequences of OSAS are correlated with the 
severity of the apneas (Roehrs, Zorick, Wittig, Conway, & Roth, 1989). Reports of 
subjective sleepiness and alertness may vary between patients with similar levels of 
objective severity; however, a clinical interview will often reveal unusual sleepiness, 
with patients reporting that they fall asleep during a variety of activities (Guilleminault, 
1994). Often, the development of sleepiness in OSAS is insidious with patients 
presenting for treatment after they have endured symptoms for a number of years (Orr, 
1997).
The most common presenting symptom in adults with OSAS is EDS (ASDA, 
1997). This symptom may be more evident to persons with OSAS or to observers 
because the perception of sleepiness varies across individuals with reported sleepiness
3
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not always being congruent with objective measures of sleep propensity. The degree of 
impairment in daytime functioning is variable and ranges from marked impairment due 
to irresistible urges to sleep to only moderate daytime sleepiness, which is usually 
unmasked only during periods of low stimulation. Patients with EDS may fall asleep 
during low stimulation activities such as watching television or during meetings. In 
severe cases of EDS, patients will report falling asleep involuntarily while eating, 
talking, or performing very important activities such as driving. The presence of EDS 
can be of particular importance in occupations that require sustained attention, high 
levels of concentration, or repetitive tasks (e.g., long-haul truck driver or nuclear power 
plant operator). The overwhelming sleepiness experienced by many patients with OSAS 
has been shown to result in a higher frequency of occupational and driving accidents as 
compared to the general population (Guilleminault, 1982; Roth, Hartse, Zorick, & 
Conway, 1980). Sleep fragmentation and sleep deprivation from OSAS can result in 
episodes of automatic behavior during which the affected person engages in semi­
purposeful but inappropriate behavior during brief episodes of involuntary sleep 
referred to as microsleeps (Aldrich, 1994). Loud and persistent snoring (i.e., vibration 
of the soft palate and posterior faucial pillars due to increased airway resistance in 
sleep) is the most common cause of referral for OSAS (Guilleminault, 1994). Snoring 
in OSAS patients is often interrupted by silences (absence of airflow), which are 
followed by loud snorting or gasping sounds and large body movements when breathing 
is resumed (Guilleminault, 1994) If a respiratory event is severe, it is not unusual for 
the affected person to raise the upper body and partially sit up in bed at the termination 
of the event, and such loud snoring and gross body movements frequently result in the 
spouse sleeping in a separate bedroom (Guilleminault, 1994). Other symptoms of sleep
4
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apnea include frequent nocturnal awakenings accompanied by sensations o f choking or 
not being able to breathe, reduced energy, significantly reduced sleep onset latencies, 
frequent morning headaches, diminished ability to concentrate, mild memory 
impairment, and increased irritability from sleep fragmentation and partial sleep 
deprivation (Guilleminault, 1994). Additionally, upper airway obstruction is associated 
with changes in esophageal and gastric pressures, which produces complaints of 
heartburn and acid reflux in some patients with OSAS (Guilleminault, 1994). Nocturia 
is a common symptom also with 28% of patients reporting at between 4 and 7 trips to 
the bathroom per night (Guilleminault, 1994). Lastly, impotence or lack of sex drive 
has been noted in approximately 28% of patients with OSAS (Guilleminault, 1994).
Certain medical conditions are associated with OSAS, and certain drugs can 
influence the severity of OSAS. Obesity (i.e., being 20% or more above ideal body 
weight) is present in approximately two thirds of patients with OSAS (Guilleminault, 
1994). Additionally, cardiovascular disease and arterial hypertension are clearly 
associated with OSAS (Shepard, 1994). CNS depressant drugs can exacerbate the 
severity of OSAS, and alcohol ingested close to bedtime has been shown to increase the 
number of complete obstructive apnea events and to prolong their duration (Issa & 
Sullivan, 1982; Scrima, Broudy, Nay, & Cohn, 1982). This phenomenon holds true for 
hypnotics and tranquilizers if taken close to bedtime because they have effects similar 
to alcohol (Sanders, 1994).
Assessment of OSAS
Approximately 74,600 patients undergo polysomnography in accredited sleep 
disorders centers each year, and about 75% of these patients are diagnosed with OSAS 
(American Thoracic Society [ATS], 1994). Although presenting complaints of loud
5
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snoring and EDS may suggest the presence of OSAS, a diagnosis can only be made 
after the patient's sleep is studied objectively by physiological means, which is usually 
conducted in a sleep laboratory. A nocturnal diagnostic polysomnography (PSG), or 
sleep study, is the best clinical method for diagnosing the presence of OSAS. 
Polysomnographic assessment of OSAS should include central and occipital measures 
of electroencephalogram (EEG), electrooculogram, electromyogram (EMG), nasal/oral 
airflow, respiratory muscle effort, electrocardiogram, and blood oxygen saturation 
(pulse oxygen; ATS, 1994). The physiological recording of respiration during an 
episode of sleep apnea reveals that airflow ceases or is greatly reduced periodically, 
which is evident at the level of the nostrils and mouth, while strain gauges 
encompassing the patient’s chest and abdomen register the continuous respiratory effort 
of the diaphragm and intercostal muscles. Transient arousals resulting from respiratory 
events (apneas or hypopneas) are apparent in the EEG and EMG channels as bursts of 
phasic activity that are easily discernible from baseline. A multiple sleep latency test 
(MSLT) can be used to determine the extent of excessive daytime sleepiness, though 
this is not essential for diagnostic assessment. The MSLT is an objective measure of 
daytime sleepiness and consists of a series of four or more nap opportunities, which are 
scheduled for every two hours beginning two hours after a night of sleep in the 
laboratory (Carskadon & Dement, 1977). The measure of daytime sleepiness for the 
MSLT is the sleep onset latency, with values five minutes or less indicating 
pathological sleepiness.
Pathophysiology and Mechanics of Upper Airway Resistance
Resistance of airflow during sleep exists on a continuum from that which is 
detectable only with special diagnostic equipment, to mild snoring, to a range o f severe
6
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blockages of the pharynx as occurs during SAHS (Guilleminault, 1994). Factors such 
as the decreased upper airway patency, that is hypothesized to stem from changes in 
neuromuscular control brought about by sleep (e.g., hypotonicity), and various 
anatomical abnormalities o f the structures surrounding the airway (e.g., excess fatty 
tissue, stenosis of the upper airway, maxillofacial abnormalities) result in increased 
resistance of airflow in the upper airway (Isono & Remmers, 1994). Moreover, 
resistance of airflow in the upper airway during wake has been found to be greater in 
patients with OSAS than in control subjects (Anch, Remmers, & Bunce, 1982).
Although the upper airway consists of the extrathoracic trachea, the larynx, the 
pharynx, and the nose, the pharynx is the only segment of the respiratory tract that is 
capable of collapsing during sleep apnea (Isono & Remmers, 1994). The pharynx is a 
specialized portion of the upper airway and has additional functions other than 
conducting gases to and from the lungs. This structure is involved in swallowing and 
phonation, and by necessity is a highly flexible structure under sophisticated CNS 
control (Isono & Remmers, 1994). During wakefulness, pharyngeal patency is 
maintained by continual neuromuscular control of the CNS and by a balance of internal 
and external airway pressures. In the absence of full neuromuscular control of the 
upper airway, such as occurs in sleep (especially REM sleep), the pharyngeal lumen 
(the total cross-sectional area that gases may pass through) of the passive pharynx is 
influenced to a greater degree by the balance of internal and external pressures sources. 
The tube law for the passive pharynx model states that the size of the pharyngeal lumen 
is determined by opposing pressure forces located within and external to the upper 
airway (Isono & Remmers, 1994). The absolute effect of these forces on the size of the 
pharyngeal lumen in the absence of muscular activity is referred to as the transmural
7
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pressure of the passive pharynx and is determined by a balance of luminal pressure (i.e., 
outward lateral pressure acting on the internal pharyngeal wall) and tissue pressure 
compressing the external wall of the pharynx, which comes form a variety of sources 
(e.g., large tongue, gravity acting on excess submandibular fat; Isono & Remmers, 
1994). The air pressure inside the pharynx differs from atmospheric pressure during 
airflow and is influenced by the acceleration of flowing gas. This acceleration of gas 
increases kinetic energy in the narrowed upper airway, and diminishes potential energy 
(i.e., luminal pressure) in the section of the pharynx below.
Two factors responsible for occlusion of the airway during an apnea are 
inspiratory flow limitation and closing pressure. Inspiratory flow limitation is the 
concept that maximal inspiratory flow through the pharynx to the lungs remains 
relatively constant despite the progressive narrowing of the pharynx and increased 
resistance to the gas flow. Thus, as resistance against the gas flow increases, more 
potential energy is lost in overcoming the friction, thus resulting in a loss of luminal 
pressure and a further reduction of airway patency. Finally, the loss of lateral wall 
pressure reaches a critical value (i.e., closing pressure) that results in the absence of the 
pharyngeal lumen (Isono & Remmers, 1994).
In contrast to the passive phase, the active phase of the pharyngeal lumen is 
stated to occur when muscles that determine the luminal air space are in a state of 
contraction, and the airway is dilated. A phasic burst of reflexual muscle contraction 
that dilates the upper airway opposes the collapsing negative pressure produced by the 
rapid airflow of inspiration (Harper & Sauerland, 1978). The action of upper airway 
musculature interacts with sources of internal and external pressure, and these muscles 
are active during wake and sleep. However, for reasons yet to be completely
8
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understood, neuromuscular control of the upper airway is decreased during sleep, and it 
is hypothesized that changes in neuromuscular input interacts with a variety of factors 
including neck flexion, positioning of the jaw, and anatomical abnormalities of the 
upper airway, all of which influence airflow through the pharynx (Isono & Remmers, 
1994). For example, when the mouth opens during sleep, the length o f the genioglossus 
and geniohyoid muscles decreases, thus diminishing the effect of efferent neural activity 
(Isono & Remmers, 1994). Consequently, the ability of muscles which dilate the 
pharyngeal lumen to compensate for losses of transmural pressure is impaired during 
sleep by a variety of factors, any of which can contribute to the pathogenesis of OSAS 
(Isono & Remmers, 1994).
Structural Abnormalities of the Upper Airway in Patients with OSAS
As stated previously, the upper airway is the final common anatomical location 
for changes in respiratory control and neuromuscular functioning that lead to sleep 
apnea (Pepin, Levy, Veale, & Ferretti, 1992). Various techniques have been used to 
examine the upper airway, and OSAS patient samples have been examined during 
waking and sleep. Lateral radiography cephalometry has revealed that the vast majority 
of patients with OSAS have abnormalities on cephalometric roentgenograms (Pepin et 
al., 1992). In a study of 155 patients with OSAS, 150 had at least two abnormalities of 
the upper airway (Jamieson, Guilleminault, Partinen, & Quera-Salva, 1986). Patients 
with OSAS have been found to have a longer and thicker soft palate as compared to 
normal subjects (De Berry-Borowiecki, Kukwa, Blanks, & Irvine, 1988; Lyberg, 
Krogstad, & Djupesland, 1989). A reduction in the size o f the posterior airway space 
below 5 mm (normal = 11mm + 1mm) and a value of greater than 24 mm (normal = 
15.4 mm ±  3mm) for the distance from the mandibular plane to the hyoid bone (anchors
9
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the tongue muscles) has been found to correlate with the A+HI independent of the body 
mass index (BMI; Partinen, Guilleminault, Quera-Salva, & Jamieson, 1988). 
Additionally, cephalometric studies have revealed that the hyoid bone tends to be 
abnormally low in persons with OSAS (De Berry-Borowiecki, et al., 1988). 
Computerized tomography (CT) of the upper airway in a sample of OSAS patients has 
shown that the cross section area of each level of the pharynx is significantly reduced as 
compared to normal control subjects (Haponik, et al., 1983). The use of CT has shown 
increased tongue volume in patients with OSAS (Lowe, Gionhaku, Takeuchi, & 
Fleetcham, 1986). Using ultrafast CT instead of conventional CT techniques, Shepard, 
Stanson, Sheedy, and Westbrook (1990) found that the most significant narrowing of 
the upper airway in OSAS patients during waking occurred at the end of expiration at 
the level of the oropharyngeal segment. A study of sleeping OSAS patients, found that 
collapse of the upper airway occurred at pressures ranging from -  0.5 to -8.9 cm H20 
(Issa & Sullivan, 1984). Airflow may be altered at various points in the upper airway, 
and such anatomical defects have a deleterious influence on the airflow mechanics. 
Determinants of Daytime Sleepiness and Impaired Functioning in OSAS
Transient arousals from sleep detectable in the EEG as bursts o f alpha waves 
and K-complexes reflect changes in CNS activity. Transient arousals from sleep often 
occur with the termination of sleep apneas and hypopneas and indicate that an 
activation of bodily defense mechanisms has occurred in response to a cessation of 
breathing. However, changes in the EEG associated with the termination of sleep- 
related respiratory events are not the only alterations in physiological variables that 
occur in OSAS. A pattern of sympathetic nervous system (SNS) responses generally 
occurs at the conclusion of an apnea, with increased heart rate being the cardinal feature
10
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
(Guilleminault, 1982). Additionally, it is not uncommon for increases in heart rate to 
reach the point of tachycardia (i.e., over 100 beats per minute in adults; Guilleminault, 
1982). Other components of SNS response include increased heart volume, constriction 
of blood vessels, and deeper and faster respiration (Guilleminault, 1994). At the 
conclusion of an apnea, respiration is resumed by homeostatic CNS respiratory 
mechanisms, which maintain blood gases in a range so that the metabolic functions of 
the body remain normal (Douglas, 1994). Evidence suggests that the hypercapnic 
ventilatory response to increasing levels of carbon dioxide plays a significant role in 
arousal from sleep during respiratory changes in OSAS, although hypoxemia, the level 
of ventilatory effort, and increased inspiratory resistance in the upper airway all make 
contributions to the respiratory arousal response that resumes breathing (Douglas,
1994). It is arguable that the arousal from sleep which occurs in response to increasing 
levels of carbon dioxide in OSAS is the most vital defense mechanism in response to 
breathing abnormalities during sleep, and commonly, arousals to the point of awakening 
are an important contributor to the decision to seek treatment (Guilleminault, 1982).
The severe sleep disruption experienced by persons with OSAS alters the sleep 
architecture and diminishes the restorative quality of sleep (Roth, Hartse, Zorick, & 
Conway, 1980). Sleep fragmentation in the form of numerous, brief arousals from sleep 
has been demonstrated to be a significant contributor to EDS in the elderly and in 
persons with certain sleep disorders such as OSAS and periodic limb movement 
disorder (Carskadon, Brown, & Dement, 1982; Walsh & Lindblom, 1997). Sleep 
fragmentation is typically manifested by discrete intrusions of alpha wave activity in the 
sleep EEG, which are referred to clinically as transient arousals from sleep. Transient 
arousals from sleep often coincide with the termination of apneas and by definition last
11
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from 3 to 14 seconds (ASDA, 1992). In cases of severe OSAS, persons may experience 
hundreds of these transient EEG changes per night (Guilleminault, 1994). The effect of 
such severe sleep fragmentation is that the sleep quality of persons with OSAS may be 
so poor that it approximates total sleep deprivation. Daytime nap studies of patients 
with OSAS have shown significantly reduced sleep onset latencies compared to those of 
normal sleepers, with OSAS patients typically falling asleep within 2 to 3 minutes on 
average during trials of the MSLT (Roth et al., 1982).
Additional evidence for the increased daytime sleepiness which results from 
sleep fragmentation comes from experimental studies in normal sleepers where 
approximations of the sleep disruption experienced by persons with OSAS has been 
shown to significantly reduce sleep onset latencies for the MSLT (Bonnet, 1985, 1986, 
1987; MaGee, Harsh, & Badia, 1987; Philip, Stoohs, & Guilleminault, 1994; Roehrs, 
Merlotti, Petrucelli, Stepanski, & Roth, 1994). Complete awakenings after each minute 
of sleep in normal subjects have been shown to result in sleep onset latencies during 
MSLT trials similar to those observed after 64 hours of total sleep loss, even after 
controlling for the total sleep time (Bonnet, 1986). Changes in the sleep architecture 
during recovery sleep in persons who have undergone experimental sleep fragmentation 
are identical to those found in persons who have undergone total sleep deprivation, with 
rebounds of stages 3 and 4 NREM sleep and REM sleep being observed (Downey & 
Bonnet, 1987). Additionally, transient EEG arousals occurring as infrequently as once 
every four minutes during sleep have been shown to result in significantly reduced sleep 
onset latencies for the MSLT, even when the total sleep time approximated that of the 
baseline polysomnography (Roehrs et al., 1994). Other forms of sleep disruption 
including shifts to a lighter stage o f sleep have been shown to contribute significantly to
12
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sleepiness as measured by the MSLT (Stepanski, Lamphere, Badia, Zorick, & Roth, 
1984). Roth et al. (1980) found that a measure of sleep disruption, which they referred 
to as arousals subsequent to respiration (which included increases in submental EMG 
activity and leg movements accompanying respiratory-related arousals), was 
significantly correlated (r = -0.67) with daytime hypersomnolence as measured by the 
MSLT
There is strong evidence to suggest that the EDS resulting from sleep 
fragmentation is the primary cause of impaired performance in persons with OSAS. 
Bonnet (198S, 1986, 1987) has demonstrated that sleep fragmentation has detrimental 
effects on daytime cognitive functioning. Subjects who were awakened after each 
minute of unambiguous sleep (a brief verbal response was required to confirm an 
awakening) performed significantly worse on a simple reaction time task, completed 
significantly fewer addition problems correctly in the Wilkinson Addition Task, and 
performed significantly worse on a symbol substitution task as compared to baseline 
(Bonnet, 198S). Similar results were obtained in a subsequent experiment where 
disruptions after each minute of sleep resulted in fewer correct addition problems and 
performance lapses for a vigilance task (Bonnet, 1986). Hit rates for a vigilance task 
were significantly impaired in healthy subjects across three levels o f sleep disruption on 
the morning following two consecutive nights of experimental sleep fragmentation 
(Bonnet, 1987). Lapses in vigilance can often be attributed to repeated microsleeps, 
during which persons who have experienced significant sleep deprivation involuntarily 
fall asleep briefly during boring or repetitive tasks (Aldrich, 1994). Furthermore, after 
36 consecutive hours of sleep deprivation, the skin conductance orienting response to 
auditory stimuli, which reflects attentional shifts and allocations o f attentional
13
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resources, has been shown to have significantly increased response latency, decreased 
response amplitude, and faster response habituation which was clearly attributable to 
sleep loss (McCarthy & Waters, 1997). Thus, physiological changes in the mechanisms 
underlying attention may also be caused by sleep deprivation and may contribute 
importantly to impaired performance in patients with OSAS.
Blood gas disturbance in the form of intermittent hypoxemia due to sleep apnea 
has been shown to be a significant contributor to impaired neuropsychological test 
performance in persons with OSAS (Bedard, Montplaisir, Malo, Richer, & Rouleau, 
1993; Bedard, Montplaisir, Richer, & Malo, 1991; Greenberg, Watson, & Deptula, 
1987). Additionally, evidence of memory and spatial skills impairments have been 
shown to occur in heavy snorers without OSAS, with performance decrements being 
significantly correlated with the number of oxygen desaturations greater than 4% during 
sleep (Telakivi et al., 1988). Greenberg et al. (1987) found that OSAS patients 
performed significantly worse than control subjects on 7 of 14 neuropsychological 
measures and on a global rating of impairment. Impairments of motor and perceptual- 
organizational abilities in patients with OSAS were significantly correlated with total 
time not breathing (i.e., number of apneas multiplied by mean duration) and the lowest 
blood oxygen desaturation. However, the global rating of impairment was not 
significantly correlated with either of these measures, but instead was correlated with an 
estimate of illness duration (Greenberg et al., 1987). Nocturnal hypoxemia from OSAS 
has also been shown to be an important contributor to impaired executive functioning 
and vigilance (Bedard et al, 1993; Bedard et al, 1991). The minimum Sa02 value 
during sleep was shown to be significantly correlated (r = -0.76) with increased reaction 
time on a vigilance task (Bedard et al, 1991). Although treatment with CPAP over a 6
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to 10 month period improved the sleep architecture, respiration during sleep, vigilance, 
and problems with memory impairment, chronic use of CPAP did not reverse deficits 
for executive and psychomotor functioning (Bedard et al, 1993). The authors concluded 
that persistent deficits observed in persons receiving CPAP treatment for moderate to 
severe OSAS were most likely the result o f the severity of nocturnal hypoxemia. It 
remains to be seen, however, whether nocturnal hypoxemia causes poor quality sleep 
that impairs functions such as attentional orienting or affects performance via 
microsleeps.
CPAP Therapy for the Treatment of OSAS
Nasal CPAP was first described as a treatment of OSAS in 1981 (Sullivan, 
Berthon-Jones, Issa, & Eves, 1981), but was not widely recognized as an acceptable 
therapy for OSAS until 1985 (Sullivan & Grunstein, 1994). The most important effect 
of CPAP on the upper airway is that it acts as an air-pressure splint, which maintains the 
patency of the upper airway by providing continuous pressure to the interior o f the 
airway that prevents it from collapsing (Sullivan & Grunstein, 1994). According to 
members of the ATS (1994), nasal CPAP is the most effective treatment of OSAS.
Nasal CPAP has been demonstrated to be superior to other major modes of treatment 
for OSAS. In a randomized, controlled trial comparing treatments for OSAS, Lojander 
et al. (1996) demonstrated CPAP to be superior to palatal surgery and to a conservative 
management condition (a minimal treatment control condition). In a randomized, 
crossover study comparing CPAP and an oral appliance (an acrylic polymer 
mouthpiece) for the treatment of OSAS, CPAP produced no treatment failures as 
compared to a failure rate of 28% for the oral appliance (Ferguson, Ono, Lowe, Keenan, 
& Fleetham, 1996).
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CPAP uses a facial mask, or some other means of interface (such as intra-nasal 
tubes) with the upper airway, connected to an air pump that generates pressure in the 
airway while also allowing the ventilation of expired carbon dioxide. Important 
therapeutic supplements that can be used with CPAP are oxygen for patients whose 
Sa02 levels do not normalize and humidification to make use more comfortable by 
reducing the tendency for CPAP to cause nasal dryness. The most common method of 
air pressure delivery is with a nasal mask, which is manufactured in standard sizes, 
although some companies offer custom fitting for patients with unusual facial contours. 
Generally, the construction of the nasal masks consists of an outer shell o f hard plastic 
with a soft inner seal constructed of rubber or rubber filled with silicone gel. One major 
variation o f CPAP pressure delivery is nasal prongs, which enter the nostril and form a 
seal around the opening of the nostril.
The first pressure generating devices for CPAP treatment were air compressors, 
which although effective, were considered by patients to be bulky and noisy. An 
advance in the CPAP delivery technology came with the replacement of air compressors 
with air blowers. Advantages of air blowers include smaller size, greatly reduced noise 
(they are more easily insulated), and their ability to compensate for a loss of mask 
pressure due to an imperfect seal with the face (Sanders & Kern, 1992). Currently 
manufactured CPAP devices are designed to deliver pressures from 2 to 20 cm H20, 
and pressures up to 10 to 12 cm H20 are usually well tolerated (Sullivan & Grunstein, 
1994). Because inhalation and exhalation are conducted through the nasal mask, it is 
necessary to provide a means for the removal of expired C02. Common ways of 
dealing with this problem are to place a small hole in the mask, or to attach a special
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valve to the mask, which serves to deflect expiratory flow out of the system. These 
devices produce an air leak of approximately 10 to IS L/min (ATS, 1994).
There are some variations in the pressure delivery of CPAP blower systems. 
Patients often find exhalation more difficult than inhalation on CPAP because they must 
exhale against the airflow. The first method of modified pressure delivery designed to 
address this problem was bi-level positive airway pressure (i.e., BiPAP), which was 
developed by the Respironics Corporation. The BiPAP system allows the inspiratory 
and expiratory air pressure levels to be adjusted independently, and was designed to 
make the positive airway pressure more tolerable. This means of pressure delivery 
allows for a higher pressure level to be set for inspiration (inspiratory positive airway 
pressure), without equivalent high pressure for expiration (expiratory positive airway 
pressure level) and the greater discomfort that this might cause. However, the 
expiratory positive airway pressure level is essential for treatment efficacy and must be 
equivalent to the effective pressure level of CPAP, which still requires patients to 
exhale against the same pressure as would be used with CPAP.
The newest variation on pressure delivery is automatic CPAP, which delivers 
varying amounts of pressure throughout the night according to the amount required to 
eliminate snoring and sleep apnea in any given sleep stage and sleep position. A 
specific range of CPAP pressures is set for the automatic CPAP device, with the lowest 
pressure being utilized at the beginning of any sleep period. The major theoretical 
advantage of automatic CPAP is increased patient comfort, because only the amount of 
pressure that is needed at any given point in the sleep period is delivered. For example, 
higher pressures are generally required during REM sleep, because of increased 
irregularity o f breathing and atonia, and when persons are sleeping in the supine
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position due to the increased collapsibility of the airway specific to this position 
(Sullivan & Grunstein, 1994). Higher CPAP pressures levels are usually required after 
the ingestion o f even moderate amounts of alcohol or any other muscle relaxant 
(Sullivan & Grunstein, 1994). The ingestion of alcohol has been shown to increase the 
number sleep apneas and hypopneas and result in a significant increase in the number of 
episodes o f oxygen desaturation in a sample of men without symptoms of OSAS 
(Taasan et al., 1981). Alcohol ingestion also has been shown to exacerbate the severity 
of OSAS (Issa & Sullivan, 1982; Scrima et al., 1982).
There are very few contraindications for the use of nasal CPAP for the treatment 
of OSAS. Nasal CPAP should not be used with patients who have sustained traumatic 
head or spinal injury that has caused leakage of cerebrospinal fluid, but otherwise, there 
are no major contraindications (Sullivan & Grunstein, 1994). When CPAP use is 
feasible for OSAS, the amount of nasal airway pressure used should restore adequate 
ventilation and blood oxygenation, and should reduce transient arousals from sleep so 
that sleep is more continuous and the sleep architecture is normalized (ATS, 1994). The 
CPAP pressure level is usually titrated in the sleep laboratory setting. Currently, there 
is no standardized procedure for CPAP titration, but the following are regarded as the 
primary objectives during a CPAP titration: (1) restoration of a normal respiration 
pattern; (2) restoration of normal blood oxygen level; (3) normalization of the sleep 
architecture; (4) elimination of airway resistance (particularly snoring), and; (S) 
reduction of breathing-related associated transient arousals from sleep to normal levels 
(ATS, 1994). A range o f CPAP pressures is used during the titration procedure with the 
primary goal being to find a pressure level that is sufficient to prevent apnea, hypopnea, 
and snoring in all stages of sleep and in all postures of sleep (ATS, 1994; Sullivan &
18
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Grunstein, 1994). Great care must be taken to examine treatment efficacy under these 
varying conditions because the supine sleep position will require a higher pressure than 
a lateral or prone sleep position, and REM sleep will require higher CPAP pressures 
(Sullivan & Grunstein, 1994).
Regular use o f CPAP by those with OSAS has been shown to alleviate daytime 
sleepiness (Frith & Cant, 198S; Kribbs et al., 1993a; Rajagopal, Bennett, Dillard, Tellis, 
& Tenholder, 1986) and to reduce waking C02 levels (Berthon-Jones & Sullivan,
1987). Improvements in cardiovascular functioning such as acute reduction of 
elevated nocturnal blood pressure levels in OSAS patients with hypertension has been 
demonstrated with the regular use of CPAP (Fletcher, 1996). Furthermore, chronic 
application of CPAP for the treatment of OSAS has also been shown to result in a 
reduction of waking blood pressure levels in OSAS patients (Fletcher, 1996). 
Additionally, chronic use of CPAP has been shown to be associated with increased 
waking upper airway dimensions (Ryan, Lowe, Li, & Fleetham, 1991). Long-term 
assessment of daytime sleepiness with the MSLT has shown continuous improvement 
of daytime sleepiness in OSAS patients treated with CPAP that was not always evident 
at the beginning of treatment, with MSLT values continuing to normalize after the first 
50 days of treatment (Meurice et al., 1997). Symptoms return quickly when CPAP is 
discontinued, and only one night’s sleep without CPAP has been shown to result in a 
return to pre-treatment levels of sleepiness and psychomotor vigilance (Kribbs et al., 
1993a).
Changes in the Sleep Architecture from CPAP Treatment
The sleep architecture of those suffering from OSAS is significantly different 
from that of normal sleepers, with OSAS patients spending reduced amounts o f time in
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SWS and REM sleep and spending increased amounts of time in stage 1 NREM (Roth 
et al., 1980). The deficit observed for SWS is a clinically significant finding because 
stages 3 and 4 NREM sleep are particularly restorative (Roth et al., 1980). If a proper 
level of CPAP pressure is titrated in OSAS patients, there is generally a large rebound 
of slow wave sleep followed by a similarly large rebound of REM sleep. These 
rebound phenomena are most dramatic during the first night o f CPAP, but rebound of 
these sleep stages is apparent for about one week after the initiation of treatment 
(Sullivan & Grunstein, 1994). Regular and proper use of CPAP treatment for OSAS 
restores the sleep architecture and reduces rates of transient arousals from sleep and 
awakenings to within normal ranges, provided there is not another comorbid sleep 
disorder (Isono & Remmers, 1994). For example, Pieters et al. (1996) showed that 
CPAP treatment in patients with OSAS significantly increased the percentage of stages 
3 and 4 NREM sleep, REM sleep, and decreased the number of arousals per hour asleep 
as compared to baseline.
Surgical Treatment for OSAS
Tracheostomy is an effective surgical intervention for the treatment of OSAS, 
but is disfiguring and can have serious complications as it is highly prone to 
opportunistic infections. Uvulopalatopharyngoplasty (UPPP) is a surgical intervention 
for OSAS in which the uvula and a large portion of the soft palate are excised, and is a 
better surgical alternative than tracheostomy (Rodenstein, 1992). Surgery is usually 
performed under general anesthesia and the operation consists of resection of roughly
1.5 cm of the free palate, followed by suturing the posterior and anterior tonsillar pillars 
together. The anterior and posterior edges of the remaining palate are sutured together 
to complete the operation. In examinations of the efficacy o f UPPP, many investigators
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have arbitrarily defined treatment responders as patients who exhibit a reduction of the 
A+HI by more than 50% from baseline. However, only a minority of patients are 
classified as UPPP responders and complete elimination of OSAS is rare (Rodenstein, 
1992). Several studies have reported success rates of less than 50% (Simmons, 
Guilleminault, & Miles, 1984; De Berry Borowiecki, Kukwa, & Blanks, 1985). 
Disregarding treatment responder status, De Berry Borowiecki et al. (1985) reported 
that 60% of patients had an apnea index of > 20 after UPPP surgery. This is an 
important result because significantly increased mortality has been noted in patients 
with an apnea index of >20 per hour (He, Kryger, Zorick, Conway, & Roth, 1988). 
Complications most commonly occurring after UPPP are transient nasopharyngeal 
regurgitation, rhinolalia, and infections (Rodenstein, 1992). Mortality may be indirectly 
increased in patients undergoing UPPP as compared to patients treated with 
tracheostomy or CPAP. In a 5-year to 8-year follow-up study of patients treated by 
either UPPP, CPAP, or tracheostomy, all of the patients who died (w = 14) were treated 
by UPPP (He et al., 1988).
Laser-assisted uvulopalatoplasty (LAUP) has been promoted as a safer surgical 
alternative than the UPPP for the treatment of OSAS (Walker, Grigg-Damberger, & 
Gopalsami, 1999). Furthermore, research suggests that treatment outcomes from the 
LAUP procedure are comparable to those obtained with UPPP in terms of reduced 
A+HI (Mickelson, 1996; Pribitkin et al., 1998). Although the LAUP procedure has 
been shown to be effective in the treatment of snoring, it has not been shown to be 
particularly effective in reducing the RDI of OSAS patients, and might only be a viable 
treatment option for patients with milder illness (Pribitkin et al., 1998).
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Non-surgical Treatments for OSAS other than CPAP
Tongue-retaining devices have been tested in large numbers of patients (Lowe, 
1994). These devices consist of custom-made mouthpieces that are designed to 
maintain the patency of the pharynx by creating suction on the tongue and extending it 
past the teeth. The devices are bulky and tolerance of their use is 50% at best (Lowe, 
1994). Additionally, patients must be able to breathe freely through the nose, which 
may be impossible given the anatomical abnormalities commonly found in patients with 
OSAS. These devices are generally only effective with patients whose OSAS is 
ameliorated by sleeping on the side and treatment generally leads to improvement rather 
than elimination of air resistance (Cartwright & Samelson, 1982). Although weight loss 
would seem to be a logical recommendation for patients with OSAS, weight loss is 
rarely ever achieved on a permanent basis and regular use of CPAP is arguably a less 
demanding and more achievable treatment regimen for OSAS than the maintenance of 
significant weight loss (Smith, Gold, Meyers, Haponik, & Bleecker, 1985). Finally, 
positional conditioning can be effective for persons who experience apnea only in the 
supine sleeping position (Cartwright, 1984; George, Millar, & Kryger, 1988). In this 
procedure, the patient is trained to avoid sleeping in the supine position, which can be 
accomplished by wearing a device (e.g., a pajama shirt with a ball sewn into the back) 
that makes sleeping on the back aversive.
CPAP Compliance
In general CPAP compliance is less than optimal and may even be less than 
adequate (Kribbs, 1997). Currently, no broadly accepted definition of CPAP 
compliance in OSAS patients has been formulated, and CPAP compliance has been 
defined variably across studies (Collard, Pieters, Aubert, Delguste, & Rodenstein,
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1997). In general, CPAP compliance has referred to the degree to which patients who 
accept this form of treatment for OSAS actually use it (Collard et al., 1997). A sample 
of the various definitions of CPAP compliance that can be found in published research 
include: self-report estimates of persistent daily use without objective verification of 
actual time used (Rolfe, Olson, & Saunders, 1991); persistent (although not necessarily 
daily) use of CPAP at the time of follow-up (Waldhom et al., 1990; Hoffstein, Viner, 
Mateika, & Conway, 1992); the average number of hours of daily use as measured from 
built-in use clocks (Pieters et al., 1996; Fletcher & Luckett, 1991); more than 3 hours 
per night of daily use (Krieger & Kurtz, 1988); at least 4 hours of use on 70% of the 
nights measured (Kribbs et al., 1993b); at least 4 hours of use per night on average 
(Rauscher, Formanek, Popp, & Zwick, 1993); and daily use averaging at least 5 hours 
per night (Meurice et al., 1994). For persons who use CPAP on nearly a daily basis, 
compliance has been found to range on average from 5 to 6.5 hours per night (Collard et 
al., 1997; Krieger & Kurtz, 1988; Fletcher & Luckett, 1991; Engleman et al., 1996). 
However, most studies using objective means of measuring CPAP use as measured by 
clocks which record the total time CPAP is on have generally found use averaging less 
than five hours per night (Berthon-Jones, Lawrence, Sullivan, & Grunstein, 1996; 
Engleman, Martin, & Douglas, 1994; Rauscher et al., 1993; Reeves-Hoche, Meek, & 
Zwillich, 1994). Additionally, a close examination of patterns of CPAP use suggests 
that there can be considerable night-to-night variability of use even in patients 
considered to be compliant (Kribbs et al., 1993b; Rauscher et al., 1993). For example, a 
study by Kribbs et al. (1993b) found that only 2 of 35 (6%) patients used CPAP for 7 
hours or more per night every night. Furthermore, Rauscher et al. (1993) discovered that 
only 30% of a sample of patients used CPAP for more than 80% of their reported time
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in bed. It is also apparent that patients may take frequent self-prescribed breaks from 
treatment during situations such as illness, travel, weekends, or may use CPAP on 
alternate nights or for only part of the night (Rauscher et al, 1993).
The earliest phase of CPAP compliance has been referred to as acceptance 
(Collard et al., 1997). A considerable barrier to implementing CPAP therapy for OSAS 
is that many patients refuse CPAP as a treatment option initially or following a full- 
night or split-night CPAP titration trial in the laboratory (Waldhom et al., 1990). 
Rauscher et al. (1993) found that 32% of patients refused a CPAP titration trial from the 
outset, and 28% of the remaining sample of patients who agreed to undergo a titration 
trial elected not to use CPAP for treatment of their OSAS. Thus, 49% of the original 
sample (N = 95) refused regular home CPAP treatment for OSAS either initially as a 
treatment option or after undergoing one night of CPAP titration in the laboratory 
(Rauscher et aL, 1993). Pieters et al. (1996) obtained similar results in a sample of 
patients with OSAS and found that 24% of patients refused CPAP as a treatment option 
after a night of titration in the laboratory.
After the initial acceptance of CPAP for home treatment of OSAS, attrition rates 
are high. In a retrospective study of 168 patients prescribed CPAP therapy, only 64% 
of patients continued to use CPAP at the time of follow-up (ranged from 1.5 months to 
78 months, Rolfe et al., 1991). Similar results for attrition have been obtained in other 
follow-up studies, with rates of compliance ranging from 65 to 68% (Nino-Murcia, 
McCann, Bliwise, Guilleminault, & Dement, 1989; Meurice et al., 1994). Although 
various follow-up intervals have been used within and between studies in attempts to 
ascertain compliance rates for CPAP, it appears that the first few weeks or, at most, the 
first few months after CPAP therapy is initiated are critical in promoting long-term
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compliance (Nino-Murcia et al., 1989; Collard et al., 1997). Most patients who 
discontinue CPAP will do so shortly after beginning treatment, and use of CPAP during 
the first month has been shown to strongly predict use at 3 months (Kribbs et al., 1993b; 
Fleury, Rakotonanahary, Tehindrazanarivelo, Hausser-Hauw, & Lebeau, 1994). 
Hoffstein et al. (1992) found that patients who quit CPAP therapy returned their 
equipment after an average of 3 months. Rolfe et al. (1991) found similar rates for 
discontinuation of CPAP with 78% of noncompliant patients stopping treatment within 
two months and 90% by four months. Conversely, for those who continue to use CPAP 
after the first few months, compliance has been shown to be very stable, with compliant 
patients continuing to use CPAP for an average of five hours per day over two 
consecutive follow-up periods covering a total of three years (Pieters et al., 1996). 
Methods of Measuring CPAP Compliance
The ATS (1994) recommends routine follow-up to evaluate a patient’s response 
to CPAP therapy, which should include some objective measurement of compliance. In 
the CPAP treatment literature, methods of measuring compliance have included 
subjective self-report of daily use and objective methods of measurement including total 
machine run time, monitored with built-in time clocks, and/or measurement of effective 
application of CPAP and patterns of use via microchips, which can record the exact 
amount of time that CPAP is at or near the prescribed pressure (Collard et al., 1997). 
Microchip technology also allows precise analysis of patterns of use with date and time 
of each instance that the machine is switched on and off (Collard et al., 1997). Early 
studies of CPAP compliance in OSAS patients yielded favorable results; however, these 
investigators did not utilize objective means to verify actual patient compliance with 
CPAP, with self-report used as the primary measure (e.g., Sanders, Gruendl, & Rogers,
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1986). Furthermore, comparisons of patients’ estimates and objective measures of 
compliance reliably show that patients overestimate their average use of CPAP by 
approximately one hour per night (Rauscher et al., 1993, Kribbs et al., 1993b). The 
introduction of objective measures o f CPAP use has allowed more accurate assessment 
of compliance. For example, using microchip technology capable of recording machine 
time on and time off, and the total time at the prescribed pressure for each day, Kribbs 
et al. (1993a) found that there was often a large variation of use across days for many 
patients.
Internal clocks by themselves may be adequate for the assessment of CPAP 
compliance, as consistent and only slight differences between machine time on and time 
at effective pressure have been found across studies; moreover, there is a very high 
correlation between these two CPAP use measures, generally on the order of r = .90 
(Collard et al., 1997). These findings have brought many investigators to the conclusion 
that monitoring compliance with an internal clock that records total hours of use is 
necessary and sufficient (Pieters et al., 1996). However, it has been argued that the use 
of this technique does not allow for an examination of patterns o f use, because only the 
average daily use time is available as opposed to the more detailed night-by-night use 
data achievable via computer microchip technology (Kribbs, 1997).
Predicting CPAP Compliance
There have been several investigations that have attempted to identify which 
patient or sleep variables might predict the degree of CPAP compliance. However, no 
consistent predictive factors have emerged, and statistically significant relations 
between the variables examined and the criterion of compliance have been shown to be 
generally weak (Collard et al., 1997). One prospective study of 47 patients with OSAS,
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which measured CPAP use covertly with an electronic recording device, found no 
significant predictors of compliance (Reeves-Hoche et al., 1994). Data analyzed in this 
investigation included pre-treatment A+HI, age, gender, BMI, education level, 
prescribed CPAP pressure, and subjective daytime sleepiness (Reeves-Hoche et al.,
1994). Employing a similar group of predictor variables, Fletcher and Luckett (1991) 
also did not find any significant predictors of hourly compliance, although it should be 
noted that the sample of OSAS patients was very small (N=  10). Moreover, initial 
severity of sleep apnea, effectiveness o f CPAP in normalizing the sleep architecture, 
blood oxygen levels, reported side effects, and prescribed CPAP pressure level were not 
shown to discriminate between compliant and noncompliant patients (Waldhom et al., 
1990).
In contrast, other studies have found significant relationships between 
polysomnographic/patient predictor variables and the criterion variables of acceptance 
and average nightly use of CPAP treatment. Significant correlations have been 
observed between the average nightly use of CPAP and the polysomnographic 
parameters of pre-treatment A+HI
(r = .37), the combined percentage of stage 1 and stage 2 NREM sleep (r = 30), and the 
combined percentage stage 3 and stage 4 NREM (r = -.31) sleep during the diagnostic 
PSG (Meurice et al., 1994). Additionally, Meurice et al. (1994) found significant 
correlations between nightly use of CPAP and the degree of improvement from baseline 
to post-treatment for the A+HI (r = -.34) and mean Sa02 during sleep (r = .38). Studies 
of CPAP compliance by Hui et al. (2001) and Bennett, Langford, Stradling, and Davies 
(1998) have also found significant correlations between the pre-treatment A+HI and 
CPAP use with correlations of r = .21 and rs= .34 being observed respectively Also,
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objective CPAP use has been found to significantly correlate with lowest Sa02 during 
the baseline study (r = -.26; Rauscher et al., 1993). In a study o f 168 patients prescribed 
CPAP, significantly more patients with both EDS and Sa02 desaturation below 75% 
were using CPAP at follow-up (Rolfe et al., 1991). However, it should be noted that 
this sample included a large number of patients who did not have OSAS and were being 
treated with CPAP for snoring, and the study did not use objective means of measuring 
compliance. A significant difference has been observed between patients with milder 
and more severe OSAS in initial acceptance of CPAP, with only 28% of mild to severe 
OSAS patients (A+HI between 15 and 30) accepting CPAP therapy versus 95% of those 
with very severe OSAS (A+HI > 60; Rauscher, Popp, Wanke, & Zwick, 1991b). 
Hoffstein et al. (1992) found that compliant CPAP users had a significantly higher mean 
BMI than non-compliant patients. Finally, full-night titration studies are often used to 
set an effective level of CPAP pressure, but, as a cost saving measure, many sleep 
disorders centers routinely conduct a 2 to 4 hour baseline and begin CPAP titration for 
the remainder of the night (i.e., split night studies) if warranted and/or feasible. Fleury 
et al. (1994) found that acceptance and compliance rates for CPAP in patients who were 
introduced to therapy during a split-night procedure were comparable to those found for 
full-night titration studies, concluding that this did not appear to be an important 
consideration in CPAP compliance. Although Strollo et al. (1996) also did not find a 
significant difference in the rate of CPAP use between patients who had undergone 
CPAP titration during a split-night procedure versus a full-night procedure, there was a 
trend for persons in the fiill-night condition to use CPAP more on average per night (5.2 
vs. 3 .8 hours per night); however, the authors caution that the study sample size was 
small (n = 24). Because significant predictors and criteria for compliance have varied
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widely among studies, it is likely that long-term compliance with CPAP in OSAS 
patients is determined by a variety of factors (Pieters et al., 1996).
The variable and weak results that have been obtained in trying to predict CPAP 
compliance from traditional objective sleep variables have been of limited value in 
predicting CPAP compliance. Bennett et al. (1998) used the new computerized 
techniques of digital subtraction of video imagery (to detect subtle arousal-related 
movements during sleep) and neural network EEG analysis (which examines sleep 
depth on a continuous scale rather than the traditional sleep staging of Rechtschaffen 
and Kales [1968] sleep scoring criteria) in an effort to find more sensitive measures of 
sleep restfulness that might be useful in predicting CPAP compliance. In this mixed 
sample that included patients with simple snoring through those having severe OSAS, 
Bennett et al. (1998) found that compliance with CPAP treatment was significantly 
correlated (r, = .39) with the movement event index, and with two measures of EEG 
sleep depth (i.e., standard deviation of sleep depth and sleep descent index) derived 
from the neural network analysis (r, = .47, r, = 48 respectively).
Research also indicates that subjective measures of CPAP satisfaction might 
predict compliance with CPAP in OSAS patients (Hoffstein et al., 1992). Engleman et 
al. (1996) specifically focused on subjective indicators o f effectiveness and compliance 
and found that subjectively measured use of CPAP was significantly correlated with 
pre-CPAP Epworth Sleepiness Scale scores (r = .22) and post-CP AP Epworth 
Sleepiness Scale scores (r = -.18). Other important relations between self-reported 
CPAP use and subjective indicators of improvement were derived from factor analysis 
(Engleman et al., 1996). CPAP compliance was correlated with positive changes in 
daytime functioning (r = .44), changes in nocturnal symptoms (r = .35), and changes in
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general functioning/symptoms (r = 46). Finally, a “nuisance factor” was associated 
with reduced compliance (r = 1S), and was especially common in those with milder 
illness (Engleman et al., 1996). In another study, Waldhom et al. (1990) observed that 
compliant patients (i.e., using CPAP at the time of follow-up) had significantly more 
subjective daytime sleepiness as assessed at baseline than noncompliant patients. 
Rauscher et al. (1991b) found that significantly more OSAS patients who reported EDS 
accepted CPAP compared to patients who reported little or no EDS. Furthermore, 
Fletcher and Luckett (1991) found that more severe baseline obstructive sleep apnea 
symptoms were significantly correlated with perceived improvement after treatment (r 
= 62). Hoffstein et al. (1992) found that significantly more patients who reported no 
subjective improvement with CPAP discontinued CPAP, which was in contrast to the 
lower discontinuation rate of patients who reported subjective benefits from CPAP 
therapy. Finally, Meurice et al. (1994) found that an improvement in a score of 
subjective daytime sleepiness measured before and after CPAP treatment was 
significantly correlated (r = -.40) with daily use of CPAP.
Side Effects and other Factors in CPAP Noncompliance
Though reports of serious complications for any mode of CPAP are rare, side 
effects are very common (e.g., skin and eye irritation, nasal dryness and congestion, and 
rhinorrhea, ATS, 1994). Hoffstein et al. (1992) found that waking up during the night 
was the most common side effect and was reported by 46% of the sample. For patients 
who refused CPAP after a titration trial, IS of 18 patients complained of having trouble 
falling asleep with the CPAP mask on (Pieters et al., 1996). Lojander et al (1996) found 
that six of eight persons who refused CPAP after a night of CPAP titration reported that 
did so because of failure to adjust to the machine. Intolerance o f the CPAP mask is a
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common complaint, with as many as 43% of patients report discontinuing CPAP 
therapy for this reason (Rolfe et al., 1991). Pepin, Leger et al. (1992) found that 50% of 
patients using CPAP complained of at least one side effect due to the nasal mask. 
Although Waldhom et al. (1990) found both compliant and noncompliant CPAP 
patients had a high rate of reported adverse reactions to CPAP (discomfort with the 
nasal mask was the most common), no significant difference between the groups was 
demonstrated for any specific complaint. Side effects have been shown to be unrelated 
to the number of months CPAP was used as assessed at follow-up (Nino-Murcia et al , 
1989). Additionally, side effects have been shown to be unrelated to the pressure level 
prescribed for home use (Pepin, Leger et al., 1992; Rauscher et al., 1993). Side effects 
have also been shown to be unrelated to self-report of CPAP use (Engleman et al.,
1996). Nino-Murcia et al. (1989) found that 50% (n = 5) of patients who quit CPAP 
within the first 2 weeks of initiating therapy did so because of anxiety. Hoffstein et al. 
(1992) found that 10% of patients complained of claustrophobia from wearing the nasal 
CPAP mask. Additionally, Kribbs et al. (1993b) found that feelings of claustrophobia 
when wearing the CPAP mask were reported significantly more often by patients who 
were irregular users o f CPAP (defined as using CPAP < 4 hours per for < 70% of days). 
Interventions Aimed at Improving CPAP Compliance
Many of those who accept CPAP for treatment of OSAS at home will 
discontinue treatment, and such patients generally abandon this mode of therapy in the 
first three months (Collard et al., 1997; Hoffstein et al., 1992). It has been suggested 
that the initial period of adjustment to CPAP is the most crucial for compliance, because 
many OSAS patients who accept CPAP therapy for home treatment quit in as little as 2 
weeks (Nino-Murcia et al., 1989). Despite the fact that noncompliance with CPAP
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treatment in OSAS patients is a widely recognized problem, surprisingly few 
interventions have been evaluated for improving CPAP compliance. Support in the 
form of weekly, followed by monthly telephone contacts was not shown to significantly 
improve objective compliance for new CPAP users as compared to a control group of 
chronic CPAP users (Fletcher & Luckett, 1991). Additionally, a study of CPAP use in 
newly diagnosed OSAS patient by Hui et al. (2000) that also included support in the 
form of daily, followed by weekly and monthly telephone calls and that had participants 
meet their physician after the first and second week o f CPAP therapy was not shown to 
significantly improve compliance. Likar, Panciera, Erickson, and Rounds (1997) 
showed improvement in hourly use of CPAP in patients who participated in one or more 
(mean = 4) two-hour group education sessions held every six months, with an average 
increase in nightly use of CPAP from 5.2 hours to 6.3 hours per night. Additionally, 
education increased nightly use by at least two hours in 10 of 34 patients (29%). 
Although these results are encouraging, the authors emphasized that there was no 
control group, and the observed improvement may have been influenced by factors 
other than the group education sessions (Likar et al., 1997). Chervin, Theut, Bassetti, 
and Aldrich (1997) compared a group of patients with OSAS who received weekly 
phone calls to troubleshoot and encourage CPAP use against a group patients who 
received written information regarding the nature o f sleep apnea and the importance of 
regular use of CPAP. Both interventions increased use as compared to a control group, 
with average nightly use being 2.7 hours greater in the information group than in the 
control group and 1.3 hours greater in the phone call group than in the control group, 
although average nightly use was significantly increased only for the information group.
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These authors also found that intervention benefited patients most when it occurred 
during the first month o f beginning CPAP (Chervin et al., 1997).
Habituation of CPAP
Habituation is generally defined as a progressive decrease in the magnitude o f a 
response that occurs with repeated presentations of an eliciting stimulus (Domjan,
1996). Habituation is a basic and common form of learning and is adaptive in the sense 
that it allows organisms to ignore inconsequential stimuli (Petrinovich, 1984). 
Furthermore, the habituation of a response represents a relatively permanent form of 
learning, with observable short-term and long-term effects on behavior (Petrinovich, 
1984). The behavioral opposite of habituation is sensitization, which was discovered 
when existing theories of habituation did not adequately account for all of the changes 
that might occur in response to repeated presentations of a stimulus (Petrinovich, 1984). 
Sensitization is generally described as an increase in the magnitude of a response 
resulting from the repeated presentation o f a stimulus that also can also have short-term 
and long-term effects on behavior (Domjam, 1996). According to the dual-process 
theory, there are separate neural mechanisms or processes for habituation and 
sensitization that act in opposition to regulate reflex responsivity (i.e., every stimulus is 
thought to elicit a behavioral response which is the net effect of the competing 
properties of habituation and sensitization; Groves & Thompson, 1970). Habituation is 
posited to occur in the stimulus-response (S-R) system, with sensitization thought to 
occur in the state system (Groves & Thompson, 1970). The S-R system is involved in 
the direct elicitation of a behavioral response by a stimulus (Groves & Thompson,
1970). The state system reflects the general level of arousal or tendency to respond and 
may be influenced by stimuli other than the stimulus that originally activated the S-R
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system as well as the original stimulus. It is believed that mild to moderate stimulation 
produces an initial increase in sensitization until a peak level is reached, which is 
rapidly followed by a decay of the response. In general, sensitization is a transient 
response, but may be prolonged when a stimulus is very salient or intense. The 
processes of habituation and sensitization are influenced by the intensity, significance, 
and timing of stimulus presentations, and both processes are hypothesized to decay with 
time. Finally, responses to eliciting stimuli that have resulted in habituation are subject 
to spontaneous recovery and dishabitution (Groves & Thompson, 1970).
Summary
Although there have been an appreciable number of studies that have attempted 
to determine factors that influence CPAP compliance, inconsistent rather than 
consistent predictors have been the norm. After ruling out the severity of the condition, 
positive reinforcement, and economic reasons as explaining factors which influence 
patient compliance with CPAP, Pieters et al. (1996) suggested that their habituation-like 
method of allowing the patients to gain experience with the CPAP device and slowly 
adapt to positive airway pressure for two to four nights in the hospital prior to the 
titration polysomnography may have resulted in a positive outcome, although this was 
not tested experimentally. Other authors have emphasized the importance of the 
manner that CPAP is introduced to the patient in the laboratory, although no scientific 
evidence or specific information about how this should be accomplished was provided 
(Sullivan & Grunstein, 1994). Furthermore, Saskin (1997) refers to the importance of 
allowing patients to acquire experience with the CPAP stimulus with the blower set “on 
a low pressure”, and states that this procedure is helpful for patients who are 
uncomfortable with the idea of CPAP, but again, no data are provided. In an
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examination of split-night versus hill-night CPAP titration, Strollo et al (1996) reported 
allowing all patients in the study to experience the CPAP stimulus prior to titration, but 
did not examine this part of their procedure specifically.
Few studies have attempted to improve CPAP compliance with specific 
interventions. The current study systematically evaluated the potential value of a 
habituation procedure in promoting adjustment to CPAP in the laboratory, using a well- 
detailed habituation method, a properly controlled design, and the appropriate statistical 
analyses. The current study attempted to fill a gap in the CPAP compliance literature 
by examining the contribution of the manner in which patients were introduced to the 
unique CPAP treatment stimulus and its influence on the acceptance and use of this 
treatment for OSAS. Currently, there is no standard practice regarding the best way to 
introduce patients to CPAP therapy, and methods vary widely across sleep disorders 
centers. The CPAP habituation procedure consisted of a 30-minute trial during which 
patients were acclimated to CPAP while experiencing a range of pressures using a 
standard nasal mask prior to undergoing CPAP titration in the laboratory. Allowing 
patients to experience CPAP prior to polysomnography with CPAP titration, while they 
were engaged in typical pre-sleep activities such as watching television or reading, was 
hypothesized to make the CPAP stimulus less arousing during sleep. Information about 
CPAP is a valuable resource for patients, but it was hypothesized that in vivo 
experience with the CPAP apparatus would produce better CPAP compliance post 
polysomnography. Undoubtedly, many sleep disorders centers provide information 
about CPAP and allow patients to experience CPAP before treatment; however, there 
have not been a published scientific study that has specifically examined the role of 
patients’ initial experience with the CPAP stimulus in the laboratory to treatment
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outcome. Given the potential health problems associated with untreated OSAS, the 
efficacy of CPAP treatment for OSAS, and the lack of good treatment alternatives, 
identifying a method to improve CPAP compliance warranted exploration.
In summary, habituation of CPAP prior to the polysomnography was 
hypothesized to facilitate the initial adjustment to the treatment, which was 
hypothesized to be reflected in the sleep architecture during the time of CPAP titration. 
Improved initial adjustment to the CPAP treatment stimulus was hypothesized increase 
the acceptance of CPAP and the degree of individual hourly compliance with CPAP 
therapy for the treatment of OSAS.
36
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Methods
The CPAP habituation study was designed to test the general hypothesis that 
habituation to the CPAP treatment stimulus prior to attempting to sleep with CPAP 
would promote the acceptance and use of this form of treatment for OSAS. All 
participants were scheduled to undergo some form of polysomnography (i.e., split-night 
or fiill-night CPAP titration procedure), in a medical sleep disorder center on the night 
of their participation in the study. The study consisted of two experimental groups and 
two control groups. Participants in the two experimental groups wore the nasal CPAP 
mask during wake and experienced a range of air pressures over a 30-minute trial on the 
evening that their sleep studies were conducted. This occurred prior to the clinical 
polysomnography. All participants, including those in the two minimal treatment 
control conditions, received information (see Appendix A) regarding the seriousness of 
OSAS, the effectiveness of CPAP in treating this condition, and the benefits that they 
could expect to derive from using CPAP regularly. Participants undergoing the CPAP 
habituation procedure received this information also because withholding information 
about such a serious medical problem would not have been in their best interest. 
Participants
Of the total o f 144 participants that were recruited for the study, 61 participants 
met inclusion criteria for the data analyses. Participants were patients referred to the 
Sleep Disorders Center of Alabama (SDA), the HealthSouth Medical Center Sleep 
Disorders Center (HMC), or the Sleep Disorders Center of the Ochsner Clinic of Baton 
Rouge (OCBR) for a clinical polysomnography (PSG). The purpose of the clinical PSG 
was to rule out the presence of OSAS with the possibility o f CPAP treatment during the 
study, or in the case of patients newly diagnosed with OSAS, to undergo a full-night
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CPAP titration trial. Participants were approached in the laboratory on the night of their 
sleep study to determine if they were interested in participating in the experiment. 
Participants were fully informed about the purpose and nature o f the study in 
accordance with the ethical guidelines of the American Psychological Association 
(1992) prior to their participation. The participants signed appropriate consent forms 
(see Appendixes B, C, and D) before any experimental procedure was undertaken. 
Participation was voluntary, and participants were informed that they could discontinue 
their participation at any time during the study without penalty. All participants 
included in the final data set experienced a CPAP titration trial during the course of the 
clinical PSG on the same night of their participation in the experiment. The 
experimenter informed the participants of the potential benefits that might result from 
participating and of the scientific knowledge that might be derived as a result of their 
participation in the experiment. Participants were followed up after they had been on 
CPAP treatment at home for an average of approximately seven weeks, at which time 
objective electronic or time counter data was collected from their CPAP device by a 
representative of the sleep disorders center.
Although an A+HI of at least five per hour meets the diagnostic criterion for the 
minimum number of events that is required per hour asleep for OSAS, only participants 
with an A+HI of at least 10 per hour were included in the study. This inclusion 
criterion was chosen in light of the current scientific literature, which shows that serious 
health consequences of OSAS are most likely in those with an A+HI of 10 or more per 
hour. Any subject deemed eligible to receive CPAP treatment by the referring 
physician was eligible for either of the experimental conditions. Chart reviews were 
conducted to screen for presenting complaints of loud and persistent snoring, EDS, and
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reports of respiratory pauses during sleep to find appropriate candidates for the study. 
Participants were not eligible for the study if they have had any previous first hand 
experience with CPAP or BiPAP. All appropriate candidates were randomly assigned 
to the experimental or control condition by means of a coin toss. Physicians assigned 
participants to the split-night or full-night titration condition based upon a clinical 
evaluation. Because three laboratories were employed to recruit and run participants, an 
effort was made to maintain a balance between the number of participants participating 
form each sleep disorder centers. However, extenuating circumstances resulted in 
relatively fewer participants coming from the OCBR. Men and women were eligible to 
participate in the study.
Procedure
Four groups of participants were utilized in the experiment. Please refer to 
Table 1 for a description of the experimental conditions, which will be followed by a 
Table 1: Description of the Groups and Relevant Procedures___________________
Split-Night Titration Full-Night Titration
Habituation/Education Group 1: Hab/Ed-SN Group 2: Hab/Ed-FN
Standardized Education Standardized Education
CPAP Habituation CPAP Habituation
Split-Night CPAP Titration Full-Night CPAP Titration
Education Group 3: Ed-SN Group 4: Ed-FN
Standardized Education Standardized Education
Sleep Disorders Inventory Sleep Disorders Inventory
Split-Night CPAP Titration Full-Night CPAP Titration
more detailed explanation of the procedures for each group, in the text. The number of 
participants for each group varied from the proposed number. The proposed n per 
group of 23 was not achieved for any of the groups. The number per group in the split-
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night conditions approached the proposed number of participants (Hab/Ed-SN = 22, 
Ed-SN = 21). However, participants for the full-night conditions were scarcer than had 
been anticipated, and as a result, an n o f only nine per group was achieved (Hab/Ed-FN 
= 9, Ed-FN = 9). The proposed number o f participants per group for the nightly CPAP 
use data analysis was derived from a consideration of a nominal alpha level of .05, an 
acceptable power of .80 (beta = .20, no more than four times alpha), two treatment 
levels, and an estimated effect size equal to one. The minimum number of participants 
needed per cell to avoid an excessive chance of a Type Q error was derived from Table 
C. 12 of Hinkle, Wiersma, and Jurs (1994). Although 17 participants was the exact 
number listed, 23 per group were proposed because the CPAP treatment literature 
suggested that only about 75% of all participants would elect to embark upon CPAP 
therapy after a undergoing CPAP titration in the sleep laboratory, and that 23 
participants per group would be needed to include at least 17 per group for the nightly 
CPAP use data analysis. The effect size chosen was based on limited information 
regarding average daily use of CPAP. The average CPAP use in new patients across 
studies has been shown to be approximately five hours per night with standard 
deviations of approximately one hour being common. Therefore, in order for this study 
to have had practical significance, it was predicted that CPAP use should be increased 
by at least one hour per night on average in those who had undergone CPAP 
habituation. Further, interventions such as information and education sessions about 
CPAP have been shown to increase use by at least one hour per night, based on the a 
review o f the CPAP treatment literature.
After they had given their written informed consent to participate, all 
participants were presented with the written educational briefing contained in Appendix
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A regarding obstructive sleep apnea syndrome and its treatment with CPAP. The sleep 
laboratory directors approved the written CPAP education, and participants received the 
written educational briefing prior to experiencing any of the other procedures. After the 
experimenter had presented the consent form and the written information, any questions 
that the participant had regarding the procedure or the nature of the research were 
answered at that time. At the conclusion of the educational briefing, participants in the 
two CPAP habituation groups (Hab/Ed-SN, Hab/Ed-FN) were fitted with a standard 
nasal CPAP mask and underwent the habituation procedure. The proper mask size was 
ensured through the use of a measuring device manufactured by the Respironics 
Corporation. Following this, participants in the CPAP habituation groups placed the 
nasal CPAP mask (which was attached to the CPAP system with a hose) over his or her 
nose, and the experimenter affixed the mask with a headgear that consisted of a web of 
four straps that looped through slots in the CPAP mask and wrapped around the 
participants head. Next the experimenter informed the participants that the CPAP 
device was going to be switched on, and they were instructed to breathe normally 
during CPAP. To ensure that all participants experienced the exact CPAP habituation 
pressures described, an air leak detection device contained in the CPAP 
monitoring/control system was used to evaluate the quality of the seal of the mask with 
the face. If the leak was below a value of 20 milliliters per minute, the mask was 
considered a good fit, and deemed as delivering the correct pressure. The trial was 
considered to have begun when the machine was switched on.
Participants in the two Hab/Ed groups experienced a range of CPAP pressures in 
a systematic fashion while awake. Pressures o f 4 cm H20 through 10 cm H20 were 
used. Patients began the trial at 4 cm H20, as this was in accordance with the usual
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starting CPAP pressure that patients were introduced to during a typical titration 
procedure. Pressure was increased in increments of 2 cm H20 every 7.5 minutes until 
each patient spent 7.5 minutes at 10 cm H20, and the CPAP habituation procedure 
lasted a total of 30 minutes with the mask on and delivering pressure. The final 
pressure of 10 cm H20 was selected because a review of the literature revealed that the 
average prescribed pressure for CPAP across laboratories was approximately 10cm 
H20 (e.g., Ferguson et al., 1990; Lojander et al., 1996; Pieters et al., 1996; Waldhom et 
al., 1990). The experimenter was present with the participants during the CPAP 
habituation procedure (with the exception of leaving the room briefly to adjust the 
CPAP pressure) to monitor for indications that the study should have been discontinued 
(e.g., panic-like response, severe discomfort), to ensure that participants remained 
awake, and to confirm that participants were wearing the CPAP mask properly during 
the procedure. All participants were instructed that they would be informed of each 
pressure increase before it occurred and that they could request that the pressure be 
lowered to the previous level if they had difficulty tolerating a pressure increase. The 
experimenter asked the participants to give a hand signal (a thumbs up) after each 
pressure increase to indicate that the trial should continue at the new pressure. If 
participants indicated that they were experiencing discomfort in response to a pressure 
increase, the pressure was lowered to the previous level, and they were encouraged to 
keep the mask on for the remainder of the 30-minute trial while continuing at the 
highest pressure that had been well-tolerated. This was done so that all participants 
included in the data analysis had an equal number of minutes of experience with CPAP 
prior to their sleep study. However, the participants were informed that they could 
discontinue the trial if they remained uncomfortable after returning to the previous
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CPAP pressure level. Participants were allowed to engage in any reasonable distracting 
activity that they chose during the procedure (e.g., watching TV, reading magazines). 
The experimenter spent approximately 45 to 60 minutes with each patient in the each of 
the study groups, including the completion of the informed consent. All participants 
were debriefed informally following the CPAP habituation trial to determine if they had 
any comments or questions regarding the CPAP habituation procedure.
The CPAP education groups (Ed-SN, Ed-FN) were minimal treatment control 
groups that did not undergo the habituation procedure. These participants were 
provided with information regarding the consequences of untreated sleep apnea and the 
benefits of undertaking CPAP therapy for the treatment of obstructive sleep apnea. In 
order to account for time spent with the experimenter as a potential confounding 
variable that could account for a positive outcome in the experiment, the experimenter 
spent an equal amount of time interacting with the control participants. The control 
participants spent their time answering questions about their sleep problems with the aid 
of the Sleep Disorders Inventory (SDI, Waters, unpublished; see Appendix E).
The only different pre-PSG information which the CPAP education control 
participants were given was that they were told they would be participants in an 
experiment who would undergo the usual laboratory procedures and would be 
compared to a second group of participants who would undergo a different procedure to 
determine if it would help this second group adjust to CPAP better. The CPAP 
education control participants were also told that the additional information that they 
provided to questions of the SDI might potentially provide a better understanding of 
adjustment to CPAP. In accordance with the normal procedures in the participating 
sleep disorders centers, all persons undergoing a sleep study with the possibility of
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CPAP were given the opportunity to get in vivo experience with the CPAP apparatus 
before undergoing their sleep study. The usual laboratory procedure was to fit persons 
with a nasal mask if they desired and to use the starting pressure of 4 cm CPAP pressure 
only. After 10 minutes, the sleep laboratory technician asked these participants if they 
wished to continue to experience CPAP or if they were satisfied and wished to 
discontinue. The CPAP education control participants could experience CPAP as much 
or as little as they desired.
Following their pre-PSG participation, each patient underwent the standard PSG 
procedures o f a split-night or full-night CPAP titration in the sleep disorders centers. 
Sleep parameter data was collected in a accordance with the standard of practice. All 
participants had electroencephalogram (EEG) electrodes (Grass Instrument silver/silver 
chloride cup electrodes, 8 mm) placed according to the 10-20 international placement 
system. Leads were attached for C4, C 3 ,0 2 ,0 1 , A2, Al, electrooculogram (EOG), 
and submental electromyogram (EMG). C3 and C4 optimally record sleep spindles and 
delta waves, and the 01 and 02  placements (located above the occipital regions) are 
particularly useful in detecting the presence of alpha rhythm and determining sleep 
onset (Guilleminault, 1982). The EOG placements were referenced to Al and A2 
(neutral sites located on the mastoid process). In addition to scalp and face electrode 
placements, EMG electrodes were attached to the anterior tibialis muscles of the left 
and right legs to detect periodic limb movements, which, if they occurred, may have 
resulted in associated arousals which could have confounded the transient arousal data. 
Respiration was be recorded with thermistors (nasal and oral airflow) and two 
respiration belts (respiratory effort) to detect the presence of any sleep-related breathing 
disorders. All sleep periods were scored according to Rechtschaffen and Kales’ (1968)
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sleep stage scoring criteria. Arousals were scored according to the American Sleep 
Disorders Association (1992) criteria.
Variables of interest in evaluating the effectiveness of the pre-sleep habituation 
procedure on sleep quality during CPAP titration included: (1) sleep onset latency 
(SOL; time elapsed from lights out to 3 consecutive epochs of unambiguous sleep or 
one epoch of sleep with a K-complex or sleep spindle); (2) percent stage 1 NREM sleep 
(% 1NREM); (3) percent combined stages 3 and 4 NREM sleep or slow wave sleep 
(SWS); (4) percent rapid eye movement sleep (REM); (5) number of spontaneous 
transient arousals per hour asleep (STA); (6) number of awakenings per hour in bed 
(No. Awake); and (7) sleep efficiency, the percent o f time asleep of the total time in bed 
(SE). CPAP compliance data was recorded by means of a microprocessor units built 
into the Sullivan Elite model CPAP machine and the Respironics Encore model CPAP 
machine, or a digital time counter in the case of the Fisher & Paykel model CPAP 
machine. Participants were made aware that their CPAP machines would record their 
CPAP usage and that their data would be examined after they had used CPAP for 
several weeks. Data were downloaded or read from each participant’s CPAP machine 
by home healthcare representatives during the routine follow-up visit or were obtained 
via mail in the form of electronic data storage cards that the participants removed from 
their CPAP machines and mailed to the OCBR. The variable of interest for the 
approximately seven-week follow-up was the mean number of hours CPAP was used 
each day.
Data Analyses
Analysis #1: Comparison of the demographic characteristics of the sample. 
Demographic Variables. (1) pre-treatment A+HI, (2) BMI, and (3) age.
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One-way ANOVA was used to compare group means for demographic measures 
to determine if there were any significant groups differences that might need to be taken 
into account during the interpretation of the results of the study.
Analysis #2: Effect of CPAP habituation on sleep during the CPAP titration PSG. 
Dependent Variables: (I) SOL, (2) % 1NREM, (3) % SWS, (4) % REM, (5) STA, (6) 
No. Awake, and (7) SE.
The following experimental hypotheses were tested:
1. The SOL during the CPAP titration will be significantly less for participants in the 
Hab/Ed groups (Hab/Ed-SN, Hab/Ed-FN) as compared to participants in the Ed 
groups (Ed-SN, Ed-FN)
2. The % 1NREM sleep during CPAP titration will be significantly less in the Hab/Ed 
groups as compared to the Ed groups.
3. The STA during CPAP titration will be significantly less in the Hab/Ed groups as 
compared to the Ed groups.
4. The No. Awake during the CPAP titration will be significantly less in the Hab/Ed 
groups as compared to the Ed groups.
5. The % SWS during CPAP titration will be significantly greater in the Hab/Ed 
groups as compared to the Ed groups.
6. The % REM during CPAP titration will be significantly greater in the Hab/Ed 
groups as compared to the Ed groups.
7. Sleep efficiency will be significantly greater during CPAP in the Hab/Ed groups as 
compared to the Ed groups.
Separate one-way MANOVAs were conducted to compare the treatment versus 
control group means (Hab/Ed vs. Ed) for the sleep variables (with the exception of
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STA) in the split-night and full-night conditions. The Hab/Ed vs. Ed comparisons for 
split-night and full-night conditions were compared separately because the sleep 
architecture varies across the night, with the % REM increasing and the % SWS 
decreasing throughout the night, and split-night participants slept with CPAP during the 
second half of the night when % REM tends to be higher and % SWS tends to be lower 
than in the first half of the night. Another important reason for analyzing the split-night 
and full-night conditions separately was to account for the first-night effect (Agnew, 
Webb, & Williams, 1966), which are consistent changes in sleep architecture that are 
attributable to the novel sleeping environment of the laboratory with its recording 
apparatus. Therefore, the adjustment to sleep in the laboratory would likely be more 
evident in the sleep architecture of the split-night participants. Pearson’s correlation 
coefficients were computed between the sleep quality and quantity variables to 
determine if they were significantly correlated for use in MANOVA. Alpha was set at 
the traditional significance level of p < OS for all tests. It was specified that if a 
MANOVA were significant, individual one-way ANOVAs (Hab/Ed vs. Ed) would have 
been conducted for each of the dependent variables to identify specific differences 
between the group means. The STA was examined separately with t-tests comparing 
the split-night and full-night conditions separately because data was not available for 
several participants due to the loss o f electronic data at the SDA and the HMC. 
Analyzing the STA separately allowed a larger n for each of the respective MANOVA 
tests. Alpha was set at the traditional significance level of p < .05.
Analysis #3: Effect of CPAP habituation on the initial acceptance of CPAP for home 
treatment of OSAS.
Dependent Variable: the proportion of acceptance of CPAP treatment for each group.
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The following experimental hypothesis was tested: Acceptance of CPAP will be 
significantly greater in the Hab/Ed groups as compared to the Ed Groups. Acceptance of 
CPAP was defined as a participant agreeing to take home a CPAP device with 
instructions to use on a nightly basis (or during each sleep period) to manage his or her 
OSAS.
Separate tests o f proportions were conducted to examine acceptance of CPAP in 
the split-night (Hab/Ed-SN vs. Ed-SN) and full-night (Hab/Ed-FN vs. Ed-FN) 
conditions to determine if severity of OSAS had an influence on acceptance. A chi- 
square test of independence was used to compare CPAP acceptance in the Hab/Ed-SN 
versus Ed-SN following polysomnography with CPAP titration in the laboratory. The 
alpha level was set at p < .05 as the criterion to reject the null hypothesis that 
acceptance of CPAP was independent of group assignment. Fisher’s exact test was 
used to compare acceptance for the Hab/Ed-FN versus Ed-FN due to the small number 
of participants in these groups. The alpha level was set at p < .05 as the criterion to 
reject the null hypothesis that acceptance of CPAP was independent of group 
assignment. Because the tests were not significant as predicted, a chi-square test of 
independence comparing the rates o f acceptance of the Hab/Ed groups versus the Ed 
groups was conducted to examine the overall proportion of CPAP acceptance collapsed 
across titration conditions.
Analysis #4: Effect o f CPAP habituation on the degree of compliance.
Dependent Variable: the mean number of hours per day of CPAP use as measured at 
approximately a seven-week follow-up.
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The following experimental hypothesis was tested: The Hab/Ed-SN and the Hab/Ed-FN 
groups will have significantly more mean hours of daily CPAP use than the Ed-SN and 
Ed-FN groups.
A two-way ANCOVA (Hab/Ed vs. Ed x SN vs. FN) test was conducted to 
compare the groups for the nightly mean number of hours of CPAP use, with the pre- 
treatment A+HI and gender as covariates. Proposed covariates were the pre-treatment 
A+HI, age, BMI, and gender, but only pre-treatment A+HI and gender were used as 
covariates after it was revealed that age and BMI had little bearing on CPAP use (please 
see the results section). For participants in the full-night titration conditions, the A+HI 
value was derived from the baseline diagnostic polysomnography. The pre-treatment 
was proposed as a covariate because persons undergoing split-night CPAP titration are 
likely to have more severe OSAS than persons undergoing full-night CPAP titration, 
and one of the principal aims of the study was to test whether CPAP habituation 
increased CPAP compliance regardless of illness severity. Alpha was set at the 
traditional significance level of p < .05.
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Results
The objective of the investigation was to evaluate a CPAP habituation method 
for introducing OSAS patients to CPAP therapy by determining its effects on sleep 
during CPAP, and its effects on subsequent acceptance and compliance with CPAP 
treatment. It was predicted that participants in the CPAP habituation treatment groups 
would have better sleep quality during the CPAP titration, would be more likely to 
accept CPAP for a trial o f treatment at home, and would be more compliant with 
treatment in terms o f average daily use of CPAP at follow-up, than participants in the 
CPAP education control groups.
Analysis of the Demographic Data
Data from 61 participants were examined in the analyses, and a total of 48 
(78.7%) men and 13 (21.3%) women were included in the final sample. The sample 
was 91.8% White (n = 56) and 8.2% African American (w = 5). The majority of the 
sample (83 6%) was recruited from the two sleep laboratories in Birmingham, Alabama, 
and approximately an equal number of persons participated from the SDA (n = 25) and 
the HMC (n = 26). The remainder of the sample (16.4%) participated at the OCBR 
(n -  10). Means and standard deviations were computed for the complete sample for 
the variables of age, BMI, and pre-treatment A+HI, which can be found in Table 2. On 
average, members of the sample were middle-aged, obese, and had severe OSAS.
Table 2. Demographic Characteristics of the Complete Sample (N= 61)
Variable M 0SD) Range
Age 47.38 (10.49) 26-75
BMI 34.18 (9.29) 19.4 - 76.8
A+HI 45.81 (29.65) 10.0 - 130.7
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Split-night CPAP titration was administered to 43 (70.5%) participants, and full-night 
CPAP titration was administered to the remaining 18 (29.5%) participants by PSG 
technicians.
Demographic data were examined to determine if there were statistically 
significant group differences for any of the demographic measures that might need to be 
taken into account when interpreting the results. One-way ANOVAs, with the Games- 
Howell multiple comparison test (see below), were used to compare the four groups for 
statistically significant differences on the demographic variables of age, BMI, and pre­
treatment A+HI. Means and standard deviations can be viewed in Table 3.










Age 49.18 (10.46) 47.19 (11.96) 43.11 (10.51) 47.67 (6.42)
BMI 33.05 (5.14) 37.12 (12.21) 27.71 (6.68) 36.53 (8.96)
A+HI 52.62 (27.76) 54.26 (33.08) 21.60 (10.42) 35.31 (28.37)
A one-way ANOVA that compared Age among the four groups was not
significant [F(3, 57) = 0.71,/? = .552 ]. The observed power at a  = .05 for the test was
.19. A one-way ANOVA for BMI among the four groups was not significant [F (3, 57)
= 2.67, p  = .056], The observed power at a  = .05 for the test was .62. A one-way
ANOVA that compared the pre-treatment A+HI among the four groups was significant
[F (3, 57) = 3.97, p  -  .012], A Games-Howell multiple comparison test was used
because the homogeneity o f variance assumption was untenable for the pre-treatment
A+HI, and revealed that participants in the Hab/Ed-FN group had a significantly lower
mean pre-treatment A+HI than participants in Hab/Ed-SN (p < 0 0 1 ) and Ed-SN
{p = .002) groups. The observed power for the test at a  = .05 was .81.
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A Chi-square test of homogeneity was conducted to examine if unequal 
proportions of men and women participated in the split-night and full-night conditions. 
This revealed a statistically significant difference for the number males and females in 
the titration conditions )?{df= 1, N = 61) = 17.86,/; < .001. Most of the male 
participants (83 .3%) participated in the split-night titration condition, and the most of 
the female participants (76.9%) participated in the full-night titration condition. A Chi- 
square test of independence conducted to examine if unequal proportions of men and 
women participated in the treatment and control conditions was not significant, £{df=  
\ ,N=  61) = 0.06,p  = .806. The results for all proportions are presented in Table 4
Table 4. Comparison of the Number of Participants per Condition by Gender
Condition Male Female ** Significance
Titration
SN 40 3 1786 1 p<  .001
FN 8 10
Group
Hab/Ed 24 7 .06 1 p = 806
Ed 24 6
Analysis of the PSG Sleep Variables during the CPAP Titration
Means and standard deviations were calculated for the purpose of comparison of 
the polysomnographic dependent variables for the habituation treatment and education 
control participants. The split-night and full night conditions were separated for these 
comparisons because of well-established differences in the sleep architecture across the 
night. These can be viewed in Table S and Table 6. Again, because of differences in 
the composition o f the sleep architecture across the night, the data for full-night and 
split-night groups were examined separately. For the purpose of examining the effect of
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SOL 11.77 (17.41) 22 14.31 (13.87) 21
SE 82.90 (10.64) 22 84.21 (10.38) 21
%Stagel 10.17 (6.66) 22 12.52 (12.62) 21
%SWS 10.26 (11.23) 22 7.57 (8.83) 21
%REM 20.95 (11.64) 22 20.40 (13.53) 21
No. Awake 2.96 (1.82) 21 3.37 (1.97) 21
STA 4.74 (5.06) 17 6.89 (8.30) 20






SOL 8.61 (11.21) 9 13.22 (13.18) 9
SE 87.38 (16.31) 9 80.44 (11.51) 9
%Stagel 4.17 (3.46) 9 9.76 (7.03) 9
% sw s 21.14 (17.95) 9 14.28 (12.24) 9
%REM 16.81 (518) 8 14.29 (7.17) 8
No. Awake 1.82 (.92) 8 2.82 (1.68) 9
STA 2.83 (2.71) 7 4.36 (2.35) 5
CPAP habituation on sleep during the CPAP titration, MANOVAs were used to 
compare the PSG variables between the treatment and control participants (i.e., Hab/Ed- 
SN vs. Ed-SN; Hab/Ed-FN vs. Ed-FN). Pearson correlation coefficients were computed 
to examine associations among the PSG sleep variables and are given in Appendixes F 
andG. The results for one-tailed MANOVAs are contained in Table 7. Neither of the
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MANOVA analyses was statistically significant at the a  = .05 level of significance.
The observed power at a  = .05 for both MANOVAs was . 14. The MANOVAs included 
all of the PSG sleep variables with the exception of STA, which was not included due to
Table 7. Examination of Habituation versus Education Sleep Architecture during 
CPAP with MANOVA
Titration Hotelling’s T2 F df P
Split-night 2.48 36 6,35 .45
Full-night 5.92 .61 6,8 .36
a large number of missing data points, and consequently, was analyzed separately. A 
one-tailed t-test that compared STA between the Hab/Ed-SN and Ed-SN groups was not 
significant [/ (35) = 0.93, p = .18], The observed power for the test at a  = 05 was .15. 
A one-tailed t-test that compared STA between the Hab/Ed-FN and Ed-FN groups was 
not significant [/(10) = 1.02,/? = .17], The observed power for the test at a  = .05 was 
.15.
Analysis of the Effect of CPAP Habituation on Acceptance of CPAP
Forty-nine participants (80.3%) accepted CPAP for a trial of treatment at home. 
The chi-square test o f independence and Fisher’s exact test (for the full-night 
comparison) were used to determine if acceptance of CPAP was independent of the 
group assignment. Acceptance of CPAP was examined separately between the split- 
night and full-night groups to determine if the severity of OSAS had an influence on 
acceptance. A chi-square test of independence was not statistically significant,
1, N= 43) = 0.09, p  = .767, for a comparison o f the proportion of participants accepting 
CPAP in the Hab/Ed-SN and Ed-SN groups. Also, Fisher’s exact test was not 
statistically significant (p = .206) for a comparison of the proportion of participants
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accepting CPAP in the Hab/Ed-FN and Ed-FN groups. The split-night and full-night 
conditions were collapsed across treatment conditions after it was determined that 
severity of OSAS did not have significant bearing on acceptance of CPAP, and a Chi- 
square test of independence computed to evaluate whether unequal proportions of 
participants accepted CPAP in the habituation treatment and education control 
conditions. The test was not significant = 61)= 1.50,/j = 221 . Refer to Tables
8,9, and 10 for exact proportions.
Variable Treatment Control i d f  Significance
CPAP
Accept 17 17 .09 1 p  = .767
Reject 5 4
Variable Treatment Control Significance
CPAP
Accept 6 9 p = .206
Reject 3 0
Table 10. Chi-square Test of Independence for CPAP Acceptance: Complete 
Sample
Variable Treatmeni Control d f  Significance
CPAP
Accept 23 26 1.50 I p  = .221
Reject 8 4
Analysis of the Effect o f CPAP Habituation on the Nightly Use of CPAP
Follow-up data for average nightly CPAP use was available for 44 (89.8%)
participants who accepted CPAP for a trial of OSAS treatment at home. Data were
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available for 33 men and 11 women. Means and standard deviations were computed for 
each o f the four groups in terms of hours of use per night and can be found in Table 11. 
Pearson product-moment correlations were computed between proposed potential 
demographic covariates (age, A+HI, BMI, and gender) and CPAP use to determine if 
there were significant correlations between the proposed covariates and CPAP use.
Table 11. Mean Hourly Use o f CPAP per Night
Group M (SD) Range n
Hab/Ed-SN 5.07 (2.34) 0 .75-7 .92 15
Ed-SN 5.26 (176) 0.37 -  7.47 14
Hab/Ed-FN 2.71 (1.93) 0 .67-3 .78 6
Ed-FN 4.42 (2.07) 1.48-8.48 9
Additionally, titration type and CPAP acceptance were included in correlation analyses
of variables relevant to the examination of CPAP use in the current study. These
correlations can be viewed in Appendix H. There were statistically significant point-
biserial correlation coefficients between gender and CPAP use (rp& = 33, p  = .03),
gender and A+HI (rPb = .36, p  = .005), titration type and A+HI (rp* = .40, p = 001), and
titration type and CPAP use (/>* = .32, p  = .036). Men tended to use CPAP more per
night than women, and men tended to have a higher pre-treatment A+HI than women.
Also, participants in the split-night groups tended to use CPAP more per night than
participants in the full-night groups, and participants in the split-night groups tended to
have a higher pre-treatment A+HI than participants in the full-night groups.
Additionally, there was a statistically significant Pearson phi coefficient between gender
and titration type (<t> = .54., p  < .001), as men tended to be assigned to the split-night
condition, and women tended to be assigned to the full-night condition by the clinic
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physicians. Finally, a t-test that was computed to assess for a possible gender difference 
among CPAP use was statistically significant [/ (42) = 2.24, p  = .03] and revealed that 
men used CPAP {M= 5.08, SD = 2.00) an average of 1.61 hours more per night than 
women (M= 3 .47, SD = 2.24). The observed power for the test at a  = .05 was .59.
A two-way ANCOVA (Hab/Ed vs. Ed x SN vs. FN) was used to compare the 
mean number of hours of daily CPAP use with pre-treatment A+HI and gender as 
covariates. Gender was included as a covariate because of the observed statistically 
significant correlation between gender and CPAP use and the statistically significant 
difference for CPAP use between men and women, and A+HI was included as a second 
covariate because of the statistically significant difference for A+HI between the 
Hab/Ed-FN group and the split-night groups. The covariate of baseline A+HI was not 
significant (F [1, 38] = 0.08, p = .781). The observed power for the test at a  = 05 
was. 06. The covariate of gender was not significant (F [1, 38] = 1.86, p  = .181). The 
observed power for the test at a  = .05 was .27. There were no statistically significant 
main effects for treatment (F[l, 38] = 1.91,/; = .175) or titration type (F[l, 38] = 1.76, 
p  = . 192). The observed power for the tests of main effects at a  = .05 was .27 and .25 
respectively. The interaction was not significant (F [I, 38] = 1.45, p  = .236). The 
observed power for the tests at a  = .05 was .22.
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Discussion
The CPAP habituation procedure plus CPAP education was not shown to be 
superior to CPAP education alone, the community standard of care for introducing 
OSAS patients to CPAP therapy. In other words, CPAP habituation did not add 
anything to CPAP education as a means of increasing CPAP compliance, and no 
statistically significant differences were observed between participants in the CPAP 
habituation treatment groups and the education control groups for any of the dependent 
variables. There were several factors that might have influenced the outcome of the 
study that will be presented after a discussion of the results.
An examination of the polysomnographic data showed that the sleep architecture 
of the CPAP habituation treatment and the education control participants was not 
significantly different for either the split-night or full-night conditions, thus 
demonstrating no statistically significant advantage to persons who experienced CPAP 
habituation. Because there were no significant differences for age, BMI, or the A+HI 
between treatment and control groups in the same titration condition, it does not appear 
that any of the demographic variables had an influence on the polysomnographic data. 
Polysomnographic variables that had not been previously examined during split-night 
CPAP titration, such as awakenings per hour in bed, transient arousals per hour asleep, 
and sleep onset latency during CPAP, also were not significantly different between 
participants in the CPAP habituation treatment and education control groups. This is 
consistent with the CPAP compliance literature, in which only weak correlations have 
been reported between polysomnographic parameters and various definitions of CPAP 
compliance. The lack of significant results might provide additional support that 
polysomnographic parameters have limited linkage with CPAP compliance. Although
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there were no statistically significant differences for the PSG variables, the values for 
sleep quality and sleep quantity variables were in the direction predicted by the 
hypotheses, with the only exception being that participants in the Ed-SN group had non- 
significantly higher sleep efficiency than participants in the Hab/Ed-SN group. An 
inspection of the PSG variables revealed that for most comparisons, the differences 
were small, and there was a large degree of variability in the data, as the standard 
deviations for most variables were large, and were larger than the means for many 
variables in the split-night data. Additionally, the differences were so small that it is 
unlikely that they would have been would be clinically meaningful even if they were 
reliable. However, given that the observed power for the MANOVAs was low (. 14), a 
lack of sufficient statistical power might account for a lack of significant findings, 
which will be discussed below.
Persons who experienced CPAP habituation were not shown to be more likely to 
accept CPAP than those who experienced the normal laboratory educational procedures 
for introducing OSAS patients to CPAP. In an examination of the complete sample, the 
percentage of persons who accepted CPAP (80.6%) after experiencing CPAP titration in 
the laboratory was similar to that found in the treatment literature (76%, Pieters et al., 
1996; 63%, Strollo et al., 1996; 78%, Fleury et al., 1994; 72%, Rauscher et al., 1993; 
83%,Waldhom et al., 1990). Additionally, although small in number and not 
statistically significant, twice as many participants who experienced CPAP habituation 
(n = 8) rejected CPAP after a night o f titration than participants who experienced 
education only (n = 4). This difference for CPAP acceptance is largely accounted for 
by the performance o f persons in the Hab/Ed-FN group, in which three persons rejected 
CPAP. In regard to the three individuals who rejected CPAP as a treatment option,
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evidence suggests that persons with milder OSAS are less likely to accept CPAP 
treatment (Rauscher et al., 1991). However, CPAP acceptance in the Hab/Ed-FN group 
raises the possibility that sensitization to the treatment stimulus might have occurred as 
opposed to habituation, which will be discussed below.
An examination of nightly use o f CPAP after sn average follow-up period of 
49.1 days did not reveal any advantage for CPAP habituation. The mean of 4.68 (SD = 
2.16) hours of CPAP use per night for the complete sample was similar to data for 
nightly CPAP use in the CPAP compliance literature (M  = 4.7, Engleman et al., 1994; 
M=  4.9, Rauscher et al., 1993; M=  4.7, Reeves-Hoche et al., 1994). Nightly CPAP use 
of at least four hours was achieved by 61.4% (n = 27) of the sample, and use of at least 
five hours of use per night was achieved by only 56.8 % (n = 25) of the sample.
Although not statistically significant, split-night participants used CPAP an average of 
1.43 hours more per more night than full-night participants, which is a clinically 
important difference. This difference might be best accounted for by severity of OSAS 
in terms of the diagnostic A+HI, which has been shown to be significantly correlated 
with nightly CPAP use (Bennett et al., 1998; Hui et al., 2001; Meurice et al., 1994). 
Although there was no significant correlation between CPAP use and the baseline A+HI 
in the current study, there was a significant correlation between titration condition and 
CPAP use, and assignment of the titration condition was based on severity. Several 
other correlations were significant. Overall, the pattern of significant correlations 
suggests that there was an association between gender, OSAS severity, and titration 
type, with women having less severe OSAS, being more likely to be assigned to full- 
night CPAP titration, and tending to use CPAP less per night than men. A comparison 
of CPAP use within the split-night sample revealed that nightly CPAP use was very
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similar for the CPAP habituation and education control participants with means of 5.07 
(SD = 2.34) and 5.26 (SD = 1.76) hours, respectively. These data were similar to the 
mean nightly CPAP use of 5.5 hours per night reported in a study by Hui et al. (2000) 
that offered newly diagnosed OSAS patients extensive support during the first month 
including daily, followed by weekly supportive telephone calls and that had participants 
meet with their physician after the first and second week of CPAP use.
An unexpected finding was that women used CPAP significantly less per night 
than men, with women using CPAP an average of 1.61 less per night. A difference of 
this magnitude would be clinically meaningful; however, the comparison of men versus 
women for CPAP use is very similar to the split-night versus full-night comparison for 
CPAP use, in that the vast majority of the data available for men is from split-night 
participants (n = 26, 78.7%) and, conversely, the vast majority of data available for 
women is from full-night participants (n = 8, 73%). Although women and men did not 
differ on the variables of age or BMI, there was a highly significantly significant 
difference (p = .005) in OSAS severity, with the men having nearly twice as many 
respiratory events per hour as the women, with a mean A+HI of 51.25 (SD = 30.65) and 
25.73 (SD = 12.64) respectively. Studies by Hui et al. (2001), Bennett et al. (1998), 
Meurice et al. (1994), suggest that severity of OSAS might best explain the gender 
difference for CPAP use. Furthermore, there was a statistically significant correlation 
between gender and A+HI in the current study. Therefore, the difference in CPAP use 
between men and women might be best accounted for OSAS severity. This is further 
supported by the fact that there was no statistically significant difference between CPAP 
use between men and women in the full-night condition with men using CPAP an 
average of 3.87 (SD = 2.30) hours per night, and women using CPAP an average of
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3.61 (SD = 2.19) hours per night (no gender comparison was made for the split-night 
because there were only three female participants). Additionally, three female 
participants were using CPAP for 45 minutes or less per day at follow-up, which had a 
great impact on the mean for CPAP use in women. If these data points were removed, 
the mean CPAP use of the remaining eight females participants would be 4.50 hours per 
day, which is very similar to the mean CPAP use for the male sample of 5.08 hours per 
day. Data from 33 men were compared against data from only 11 women, and if more 
female participants had been included in the sample, the impact of extreme these scores 
would have been attenuated.
One explanation for the lack of statistically significant findings for the CPAP 
habituation procedure was generally low statistical power for the tests. Power was very 
low for the MANOVAs in particular, with an observed power of only . 14 for each 
analysis. The power of MANOVA is affected by the factors of sample size, effect size, 
and the degree to which the dependent variables are correlated (Stevens, 1980). The 
factors of sample size and effect size have the most bearing on the lack of significant 
findings for the PSG variable data analysis. The sample size achieved in the current 
study was less than proposed, which was particularly true for the full-night conditions. 
The number of participants available for data analysis would have been decreased 
further if STA had been included in the MANOVAs, which is why this PSG variable 
was analyzed separately. Unfortunately, STA was missing for several participants due 
to the loss of electronic data by clinic personnel at the SDA and HMC. Increasing the 
sample size would have improved power for the split-night PSG analyses to a small 
degree. The addition of participants in the full-night groups might have improved 
power to a greater degree than the addition of subjects to the split-night groups
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considering that the number per group was particularly small. Although an exact post 
hoc estimate of power for the CPAP acceptance analysis was not calculated, observed 
power for these tests would likely be comparable to the low power observed for the 
other analyses (Fleiss, 1981). This is particularly applicable to the acceptance data for 
the small number of full-night participants. In regard to CPAP use, a large effect size 
had been estimated for the CPAP habituation procedure. The outcome of the study, 
particularly when examining the split-night sample, suggests that any positive effect 
that the CPAP habituation procedure might have produced for CPAP use would be quite 
small even if it were statistically significant. One of the primary research goals was to 
not only produce a statistically significant difference in CPAP use with CPAP 
habituation, but to produce a clinically meaningful improvement of at least one hour of 
CPAP use per night beyond the level of nightly CPAP use that has been reported 
without such an intervention.
An examination of factors that might have negatively impacted the research 
methodology requires consideration when interpreting the results of the study. One 
problem that was unknown at the beginning of the study was the possibility that 
participants from the SD A and the HMC would receive a benzodiazepine hypnotic 
medication during CPAP. The physicians and the clinic support staff informed the 
patients that if they experienced difficulty sleeping with CPAP, they would receive S 
mg of zolpidem (Ambien), and that the medication could be administered a second time 
if patients continued to have difficulty sleeping with CPAP. A routine physician order 
for the technicians to administer 5 mg of zolpidem to patients who were not asleep after 
one hour on CPAP resulted in a large number (n = 23) of potential participants being 
eliminated from the study. Sixty-one percent (n = 14) of participants who received
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zolpidem were in the education control groups. This was an uncontrolled source of 
variance that could not be corrected by the investigator. The use of the hypnotic 
medication was a serious potential confound, given that the purpose of the study was to 
evaluate the effectiveness of CPAP habituation in promoting adjustment to and 
acceptance of CPAP, because it would have offered a competing explanation for 
adjustment to CPAP for those who received it. More importantly, it is arguable that the 
participants who received the hypnotic medication would have continued to experience 
difficulty in adjusting to CPAP without it, which very likely would have been reflected 
in poor sleep architecture and greater difficulty accepting and using CPAP, i.e., they 
might have expected to have a more negative experience with the CPAP titration trial 
because of their tendency to sleep onset and/or sleep maintenance insomnia. As a 
result, participants who received zolpidem were excluded from the analyses, and thus 
participants who represented an important segment of the patient population and who 
might have benefited most from CPAP habituation, could not be included in the current 
sample. Equally important, the exclusion of participants who received zolpidem might 
have had a positive impact on the results by artificially inflating the percentage of initial 
acceptance of CPAP that was observed for the complete sample.
A different segment of the population that was under-represented in the current 
study was persons aged 65 and older as the vast majority of potential participants in this 
age group could not be recruited from the SDA and the HMC because Medicare was 
their primary insurance provider, which required them to receive their CPAP devices at 
a location other than the SDA (HMC patients also received their CPAP devices at the 
SDA). Only one participant from the OCBR was included from this age group, and no 
follow-up data CPAP was available for this individual. This limited the ability to
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generalize the findings of the study to persons aged 6S and older, a highly significant 
population given the tendency for OSAS to occur more frequently and to be more 
severe in patients as they age. The impact of the virtual exclusion of persons aged 6S 
and older is likely to be limited in view of a study by Parish, Lyng, and Wisbey (2000), 
which showed that CPAP use in persons aged 65 and older was very similar to that of 
persons under age 65.
A methodological problem of the study that should be noted was the use of more 
than one data collection site, which might have compromised experimental control in 
terms of the research and clinical procedures. A consequence of utilizing three data 
collection sites was that different clinic personnel and experimenters interacted with the 
patient samples at the SDA and the HMC versus the OCBR. Data collection was 
pursued at the OCBR in response to a five-month delay in beginning the data collection 
at the SDA, and the unavailability of the Sleep/Wake Disorders Center at the University 
of Alabama at Birmingham as a data collection site that had been proposed originally. 
Data collection was relocated from the SDA to the HMC due to a decision by the 
administration to move the vast majority of potential participants to the HMC for 
insurance purposes. Because the Birmingham data collection sites were under the same 
management and used the same clinic personnel, data from the SDA and HMC were 
combined, and compared with data from the OCBR. Comparisons of the Birmingham 
vs. OCBR data collection sites between participants from the same group with Mann 
Whitney U revealed statistically significant differences for SOL (U = 10.00, p  = .026) 
and STA (U = 6.00, p  = .023) for the Hab/Ed-SN participants, and also revealed 
statistically significant differences for STA ((/ = 5.00, p  = .007) and SE (U = 8 50, p  = 
.018) for the Ed-SN participants. The observed differences suggest that there might
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have been important environmental or procedural differences between the sleep 
disorders centers. As efforts were made to administer the procedures of the study and 
the CPAP titration in the same manner to all of the participants, it is possible that 
idiosyncratic inter-laboratory differences in the scoring of polysomnograms might 
account for the differences observed in the PSG variables. However, the overall impact 
o f the differences for the PSG variables between participants from the SDA and the 
HMC versus the OCBR was mitigated by the fact that participants from the OCBR 
represented a small proportion (16.39%, n = 10) of the sample, and that those 
participants were evenly distributed between the split-night groups (Hab/Ed-SN, n = 4; 
Ed-SN, n = 4) and the full-night groups (Hab/Ed-FN, n = 1; Ed-FN, n = 1) for the PSG 
data analyses. It is very important to note, however, that there were no statistically 
significant differences for CPAP acceptance or CPAP use between participants from the 
Birmingham data collection sites and the OCBR data collection site.
Another methodological consideration was that the CPAP habituation 
procedure, which consisted of only one 30-minute exposure to different CPAP 
pressures, might have been inadequate to promote complete habituation to the CPAP 
stimulus. Edinger and Radtke (1993) demonstrated that a gradual desensitization 
procedure, which included wearing the CPAP mask with pressure for one hour per day 
for five consecutive days, allowed an individual who had been unable to tolerate CPAP 
to be compliant with CPAP as measured at a six-and-one-half-year follow-up. In the 
context of the Edinger and Radtke (1993) study, the CPAP habituation procedure in the 
current study consisted of only a single trial and was brief, with only 30 minutes of in 
vivo experience for participants. Although this case report by Edinger and Radtke
(1993) addressed desensitization as opposed to habituation, it does suggest that a series
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of habituation trials and trials of longer duration might have been beneficial. Such a 
procedure appears to have merit in particular for patients who experience noteworthy 
anxiety during CPAP, as anxiety has been shown to be a factor in reduced CPAP 
compliance (Kribbs et al., 1993b; Nino-Murcia et al., 1989). There also is a remote 
possibility that sensitization, rather than habituation, might have occurred for 
participants in the Hab/Ed-FN group. However, the evidence available is contrary to a 
hypothesis of sensitization in the current study. An examination of the effect of the 
CPAP habituation procedure showed that only 4 of 69 (5.7%) participants who agreed 
to undergo the CPAP habituation procedure chose to end the procedure early, and 
consequently were no longer eligible for the study An identical number of participants 
requested to settle on the next to highest CPAP habituation pressure level of 8 cm H20 
as their final habituation setting but were able to complete a 30-minute trial with CPAP. 
Conversely, 61 of 69 (88.4%) of those who agreed to undergo the CPAP procedure 
experienced no difficulty tolerating the final pressure setting of 10 cm H20, and 65 of 
69 participants (94.2%) were able to complete a 30-minute trial o f CPAP habituation. 
However, given that that CPAP habituation did not prove useful in the Hab/Ed-SN 
group and that any possible benefits from CPAP habituation procedure would be small, 
it does not appear that it would be beneficial to include more participants in the fiill- 
night groups. In fact, it if is the case the CPAP habituation procedure resulted in 
sensitization or worse outcome in patients with milder OS AS, it would be harmful and 
unethical to recruit more participants using the procedure as it is currently designed.
Finally, given that acceptance and compliance with CPAP in the current sample 
of OSAS patients was comparable to what has been observed in the literature, the issue 
of what degree of compliance is beneficial warrants discussion. It has been established
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that OS AS patients regarded as being compliant with CPAP are sleeping without 
treatment for large parts of the night (Kribbs et al., 1993b, Rauscher et al. 1993; Pieters 
et al. 1996). This is a very important observation because a study of new CPAP users 
demonstrated that the residual benefit o f CPAP after it was removed following four 
hours of sleep was very limited, resulting in a mean A+HI of 34.9 for the rest of the 
night without CPAP (Hers et al., 1997). Similar results were obtained in a study of 
persistent CPAP users (average treatment duration o f 8.43 months) that examined sleep 
after removal o f CPAP following the first four hours of sleep, which again, showed that 
patients experienced unequivocal sleep apnea (mean A+HI = 28.7) for the remainder to 
the night (Rauscher, Popp, Wanke, & Zwick, 1991a). However, there also is some 
evidence to suggest that less than optimal use of CPAP may yield some benefits. A 
study by Engleman et al. (1994) showed statistically significant improvement in OS AS 
patients on the MSLT, OSAS symptom ratings, mood, and cognitive performance with 
objectively monitored CPAP use that averaged only 3.4 hours per night after a four- 
week follow-up. However, it should be noted that the mean MSLT value of 7.2 minutes 
to sleep onset remained in a range that is considered indicative of moderate to severe 
daytime sleepiness, and the other observed improvements were small.
In summary, the CPAP habituation procedure was not demonstrated to add any 
benefit to CPAP education in an examination of sleep quality during CPAP, acceptance 
of CPAP, and nightly use of CPAP There were no significant differences between the 
CPAP habituation/education treatment groups and education control groups on any of 
the variables examined. Approximately 80% of the participants agreed to a trial of 
CPAP treatment at home, which was comparable to initial acceptance rates for CPAP in 
the treatment compliance literature. The average nightly CPAP use for the complete
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sample was 4.68 hours, which was also comparable with average nightly use of CPAP 
that has been reported in the CPAP compliance literature. Men were found to use 
CPAP significantly more per night than women, but this difference is most likely 
accounted for by severity of OSAS as men had twice as many respiratory events per 
hour than women. There were several factors that might have influenced the results of 
the study, most notable of which were the exclusion of potential participants who had 
difficulty adjusting to CPAP and received a hypnotic medication during CPAP, and the 
exclusion of patients aged 65 and older because of insurance coverage considerations. 
Additionally, a low statistical power was observed, which limited the ability to detect 
statistically significant differences.
The goal of the present study was to address a gap in the CPAP compliance 
literature regarding the importance of the manner in which OSAS patients are 
introduced to CPAP therapy and its effect on acceptance and compliance. The CPAP 
habituation procedure was designed in response to problems that had been reported in 
the CPAP compliance literature including poor sleep with CPAP and the experience of 
anxiety in some OSAS patients who were non-compliant with CPAP treatment. Future 
research with CPAP compliance could address a number of issues. Interventions might 
be tailored to the needs of more specific OSAS patient populations For persons with 
milder OSAS, a greater emphasis on education such as that reported by Likar et al., 
(1997), which includes continuing education throughout treatment and that emphasizes 
the progressive nature of OSAS might be useful for long-term compliance with CPAP. 
Replication of the findings o f Edinger and Radtke (1993) in a small series of patients 
would lend much greater support for use o f their method of CPAP desensitization in 
persons who experience significant anxiety during CPAP. Finally, although it appeared
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that severity o f OSAS accounted for an observed gender difference in nightly CPAP 
use, research specifically addressing possible gender differences for CPAP compliance 
is lacking. More women are being diagnosed with OSAS and a recent study by 
O’Connor, Thomley, and Hanley (2000) found that the ratio of men to women for mild 
OSAS (classified as an A+HI of 5 to 25) was 2.2 to 1 and was 3.2 to 1 for all OSAS 
patients in their sample. O’Connor et al. (2000) also noted that 62% of women in their 
sample experienced the majority of the OSAS in REM sleep as compared to 24% of 
men. Such a difference suggests that it would be worthwhile to conduct research 
focusing on possible gender differences for CPAP compliance. Given that OSAS has 
been shown to be associated with ischemic heart disease (Hung, Whitford, Parsons, & 
Hillman, 1990) and increased mortality (Partinen, Jamieson, & Guilleminault, 1988) 
and that CPAP is clearly the treatment of choice for OSAS, the search for means to 
increase CPAP compliance should be continued.
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Appendix A
Standardized CPAP Education
What is nasal continuous positive airwav pressure and how does it work?
Nasal continuous positive airway pressure or CPAP delivers a continuous stream of 
pressured air through your nose that prevents your airway from collapsing during sleep. 
It is a safe and extremely effective treatment for sleep apnea, which has been in use for 
almost 20 years.
Health benefits o f CPAP therapy for sleep apnea syndrome.
There are several important reasons that guided your doctor to order a sleep study with 
CPAP for you. An immediate positive consequence of using CPAP is that many 
persons notice a significant decrease in sleepiness, which is accompanied by increased 
feelings of energy and wellbeing. A more long-term, and possibly more important 
consequence of using CPAP is decreased risk for serious medical problems, which 
might be caused by untreated sleep apnea. Such problems include hypertension, heart 
and lung problems, and stroke. Persons with untreated sleep apnea have also been 
shown to have a higher incidence of serious automobile and work accidents resulting 
from irresistible urges to sleep. Even if you do not experience excessive sleepiness, the 
regular use of CPAP every time you sleep for the whole time you are asleep is very 
important in protecting you from the other problems that untreated sleep apnea might 
cause. Finally, research has shown that even one night of sleep without CPAP results in 
a return to how persons with sleep apnea were feeling and functioning before they 
began using CPAP to treat their sleep apnea.
What to do if there are problems with vour CPAP therapy.
CPAP therapy works best when it is used every time you sleep for the entire time that 
you are in bed. If you experience any problems with CPAP, which are causing you to 
not use your machine or to use it less than all night, every night, call your home 
healthcare company representative at (20S) S99-1020 for Alabama residents or (225) 
767-1403 for Louisiana residents. Many problems with CPAP can be eliminated or 
reduced.
81
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Appendix B
Consent Form for Participation in CPAP Adaptation, Form A 
EXPERIMENTAL GROUP
1. Study Title: Examination of a Method for Increasing Adjustment to and
Compliance with Nasal Continuous Positive Airway Pressure 
(CPAP) in Persons with Obstructive Sleep Apnea Syndrome.
2. Performance Sites: Sleep Disorders Center of Alabama, Inc. and HealthSouth
Medical Center Sleep Disorders Center
3. Investigators: Principal Investigator: Jack A. Johnson, Jr., MA. Mr. Johnson
can be reached at (205) 982-9437 from 5:30 p.m. to 7:30 p.m.
Sub-Investigator. G. Vernon Pegram, Ph D. Dr. Pegram can be 
reached at (205) 599-1020 or (205) 934-7110 from 8 a.m. to 5 
p.m.
4. Purpose of the Study: To examine a method that may help patients to adjust
better to nasal Continuous Positive Airway Pressure 
(called CPAP) treatment for sleep apnea.
5. Subject Inclusion: Any person age 19 or older who has been referred by his or her
physician for a sleep study with CPAP (or with CPAP if 
indicated) is eligible for participation in this study. Only eligible 
persons have been invited to participate. Persons who have had a 
severe head or spinal injury that resulted in leakage of 
cerebrospinal fluid (the fluid that surrounds and cushions the 
brain) are not eligible to participate.
6. Number of Subjects: 92 Total People will participate in the experiment.
7. Study Procedures: All research subjects will be spending the night in the sleep
laboratory for a diagnostic evaluation, which might include a 
CPAP trial aimed at finding a proper level of treatment (air 
pressure) for obstructive sleep apnea, a routine procedure for 
persons who have this sleep disorder. Some persons may not 
receive a CPAP trial during the course of the sleep study if they 
do not have obstructive sleep apnea or if the degree of their 
illness does not clinically require CPAP treatment. The 
diagnostic sleep study will occur immediately following each 
subject’s participation in the research study. CPAP delivers a 
constant stream of pressurized air through your nose, which 
prevents you from stopping breathing during sleep. There will be 
no change in the way that CPAP is normally used in the Sleep
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Disorders Center o f Alabama, Inc. or the HealthSouth Medical 
Center Sleep Disorders Center (depending on which sleep 
laboratory you are having your examination) with the only 
difference being that you will wear the CPAP mask with air 
pressure before bedtime while you are not in bed and not 
attempting to fall asleep. The total time that you will wear the 
CPAP mask with pressure is approximately 30 minutes, during 
which time you will experience a range of gradually building 
CPAP pressures that is commonly experienced by persons during 
the course of a sleep study with CPAP. You will be started on 
the lowest pressure setting that is normally used, and the pressure 
will be increased in steps until it reaches the average pressure 
setting that is most commonly required to prevent sleep apnea. 
You will experience each of the four pressure settings for exactly 
seven and a half minutes each. The pressure will be increased 
every seven and a half minutes and will increase a total o f three 
times before the experiment is finished. During the time you are 
wearing the CPAP mask, you may engage in any relaxing activity 
that you choose including watching television or reading. Data 
from your sleep study and home CPAP use (if you are prescribed 
CPAP) will be compared against persons receiving the routine 
laboratory procedures. All persons will receive written 
information. Your participation will not reduce or modify 
information that is normally gathered during the course of a sleep 
study. Finally, the proposed study is not an experimental 
procedure, but rather is a variation of the CPAP procedure, which 
has been designed, with the aim of making adjustment to CPAP 
easier.
8. Benefits: This study may benefit you in your adjustment to CPAP and will
further scientific knowledge in the field of sleep medicine 
concerning the treatment of obstructive sleep apnea syndrome.
9. Risks/Discomforts: One risk is that some persons report experiencing anxiety, which
may take the form claustrophobia, why wearing the CPAP mask. 
In general, there is only one major reason that CPAP should not 
be used for the treatment of sleep apnea. CPAP should not be 
used with persons who have suffered a very severe head or spinal 
injury that caused leakage of cerebrospinal fluid (the fluid which 
surrounds and cushions the brain). As mentioned above, persons 
who have had an injury of this nature are not eligible to 
participate.
10. Right to Refuse: You have the right to end your participation in this research study
at any point that you choose and for any reason that you might 
have without penalty to yourself. Choosing to drop out o f the 
study will not affect the treatment that you will receive during
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your sleep study tonight or at any other time regarding your sleep 
apnea.
11. Privacy: The results of this study may be published in a research paper,
but your identity or the fact that you have participated in this 
study will never be made available to public or any other agency.
Your participation in this research study will be kept confidential. 
However, during the study, representatives from the US Food and 
Drug Administration (FDA) will be allowed to review your 
medical records that relate to the study. The Baptist Health 
System Human Research Review Board may also review these 
records. The records will identify you only by your initials and 
an assigned research study number, not by your name.
When you sign the consent document, you are giving your doctor 
permission to release your research study medical records for 
review. The representatives described in the paragraph above 
will use these records only to carry out their obligations 
associated with this study. Every effort will be made to ensure 
that your study records are not used for any other purpose, or 
given to anyone else, except when required by law.
12. Financial Information: You will not be paid to participate in this study, and there
will be no cost to you for participating.
The Baptist Health System Inc, Sleep Disorder Center of 
Alabama, and Mr. Jack Johnson have made no provision 
for monetary compensation in the event of physical illness 
and/or injury resulting from this research study. In the 
event of such injury, medical treatment is available but is 
not free of charge. There is no monetary (or other) form 
of compensation for my participation in this study.
If you have any questions about compensation or medical 
treatment for research-related injuries, contact G. Vernon 
Pegram, Ph.D. or Mr. Jack Johnson at the Sleep Disorder 
Center of Alabama at 599-1020.
13. Alternatives: Currently, CPAP is the best treatment for sleep apnea
for most persons. Your doctor is available to discuss other 
treatment options with you. The current study is not a treatment, 
but rather an examination of a way of helping people adjust to a 
treatment that they might be prescribed by their doctors after they 
experience CPAP in the laboratory during sleep.
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14. Unforeseeable Risks: There are no potential risks that a person might suffer
from resulting participation in this study.
15. Injury/Illness:
16. New Findings:
If you have questions about this study or you experience any 
unexpected adverse event (side effect) while you are participating 
in this study, G. Vernon Pegram, Ph.D. or Mr. Jack Johnson 
should be contacted at (205) 599-1020 or (205) 934-7110. He 
will be available to answer your questions before, during, and 
after the study.
If any significant new findings occur during the course of the 
study including problems that others who have participated have 
experienced in the study, you will be informed of this by one of 
the investigators listed above.
17. How to Learn More About Your Rights as a Reseach Subject:
If you have any questions about your rights as a research subject, 
contact the Baptist Health System Human Research Review 
Board, 800 Montclair Road, Birmingham, AL 35213, telephone 
205/592-5700.
18. Signatures: The study has been discussed with me and all my questions have 
been answered. I may direct additional questions regarding study 
specifics to the investigators. I agree to participate in the study 
described above and acknowledge the investigator’s obligation to 
provide me with a signed copy of the consent form.
Subject Signature Date
The study subject has indicated to me that he/she is unable to 
read. I certify that I have read this consent form to the subject 
and explained that by completing the signature line above, the 
subject has agreed to participate.
Signature o f Reader Date
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Appendix C
Consent Form Tor Participation in CPAP Adaptation, Form B 
CONTROL GROUP
1. Study Title: Examination of a Method for Increasing Adjustment to and
Compliance with Nasal Continuous Positive Airway Pressure 
(CPAP) in Persons with Obstructive Sleep Apnea Syndrome.
2. Performance Sites: Sleep Disorders Center of Alabama, Inc. and HealthSouth
Medical Center Sleep Disorders Center
3. Investigators: Principal Investigator: Jack A. Johnson, Jr., MA. Mr. Johnson
can be reached at (205) 982-9437 from 5:30 p.m. to 7:30 p.m.
Sub-Investigator: G. Vemon Pegram, Ph.D. Dr. Pegram can be 
reached at (205) 599-1020 or (205) 934-7110 from 8 a m. to 5 
p.m.
4. Purpose of the Study: To examine a method that may help patients to adjust
better to nasal Continuous Positive Airway Pressure 
(called CPAP) treatment for sleep apnea.
5. Subject Inclusion: Any person age 19 or older who has been referred by his or her
physician for a sleep study with CPAP (or with CPAP if 
indicated) is eligible for participation in this study. Only eligible 
persons have been invited to participate. Persons who have had a 
severe head or spinal injury that resulted in leakage of 
cerebrospinal fluid (the fluid that surrounds and cushions the 
brain) are not eligible to participate.
6. Number o f Subjects: 92 Total People will participate in the experiment.
7. Study Procedures: All research subjects will be spending the night in the sleep
laboratory for a diagnostic evaluation, which might include a 
CPAP trial aimed at finding a proper level o f treatment (air 
pressure) for obstructive sleep apnea, a routine procedure for 
persons who have this sleep disorder. Some persons may not 
receive a CPAP trial during the course of the sleep study if they 
do not have obstructive sleep apnea or if the degree of their 
illness does not clinically require CPAP treatment. The 
diagnostic sleep study will occur immediately following each 
subject’s participation in the research study. CPAP delivers a 
constant stream of pressurized air through your nose, which 
prevents you from stopping breathing during sleep. There will be 
no change in the way that CPAP is normally used in the the Sleep
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Disorders Center of Alabama, Inc. or the HealthSouth Medical 
Center Sleep Disorders Center (depending on which sleep 
laboratory you are having your examination). You and others 
people in the group that you are participating in will receive the 
routine clinical care that is the current community standard of 
care in a sleep disorders center that has been accredited by the 
American Sleep Disorders Association. You will not be deprived 
of any preparations that are used to get people ready for their 
sleep studies. Data from your sleep study and home CPAP use 
(if you are prescribed CPAP) will be compared against persons 
receiving a variation of normal laboratory procedures, which is 
believed might make their adjustment to CPAP easier. All 
persons will receive written information. Your participation will 
not reduce or modify information that is normally gathered 
during the course of a sleep study. Finally, the proposed study is 
not an experimental procedure, but rather is a variation of the 
CPAP procedure, which has been designed, with the aim of 
making adjustment to CPAP easier.
8. Benefits: This study may benefit you in your adjustment to CPAP and will
further scientific knowledge in the field of sleep medicine 
concerning the treatment o f obstructive sleep apnea syndrome.
9. Risks/Discomforts: One risk is that some persons report experiencing anxiety, which
may take the form claustrophobia, why wearing the CPAP mask. 
In general, there is only one major reason that CPAP should not 
be used for the treatment o f sleep apnea. CPAP should not be 
used with persons who have suffered a very severe head or spinal 
injury that caused leakage of cerebrospinal fluid (the fluid which 
surrounds and cushions the brain). As mentioned above, persons 
who have had an injury of this nature are not eligible to 
participate.
10. Right to Refuse: You have the right to end your participation in this research study
at any point that you choose and for any reason that you might 
have without penalty to yourself. Choosing to drop out of the 
study will not affect the treatment that you will receive during 
your sleep study tonight or at any other time regarding your sleep 
apnea.
11. Privacy: The results o f this study may be published in a research paper,
but your identity or the fact that you have participated in this 
study will never be made available to public or any other agency.
Your participation in this research study will be kept confidential. 
However, during the study, representatives from the US Food and 
Drug Administration (FDA) will be allowed to review your
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medical records that relate to the study. The Baptist Health 
System Human Research Review Board may also review these 
records. The records will identify you only by your initials and 
an assigned research study number, not by your name.
When you sign the consent document, you are giving your doctor 
permission to release your research study medical records for 
review. The representatives described in the paragraph above 
will use these records only to carry out their obligations 
associated with this study. Every effort will be made to ensure 
that your study records are not used for any other purpose, or 
given to anyone else, except when required by law.
12. Financial Information: You will not be paid to participate in this study, and there
will be no cost to you for participating.
The Baptist Health System Inc, Sleep Disorder Center of 
Alabama, and Mr. Jack Johnson have made no provision 
for monetary compensation in the event of physical illness 
and/or injury resulting from this research study. In the 
event of such injury, medical treatment is available but is 
not free of charge. There is no monetary (or other) form 
of compensation for my participation in this study.
If you have any questions about compensation or medical 
treatment for research-related injuries, contact G. Vernon 
Pegram, Ph.D. or Mr. Jack Johnson at the Sleep Disorder 
Center of Alabama at 599-1020.
13. Alternatives: Currently, CPAP is the best treatment for sleep apnea
for most persons. Your doctor is available to discuss other 
treatment options with you. The current study is not a treatment, 
but rather an examination of a way of helping people adjust to a 
treatment that they might be prescribed by their doctors after they 
experience CPAP in the laboratory during sleep.
14. Unforeseeable Risks: There are no potential risks that a person might suffer
from resulting participation in this study.
15. Injurv/Illness: If you have questions about this study or you experience any
unexpected adverse event (side effect) while you are participating 
in this study, G. Vernon Pegram, Ph D. or Mr. Jack Johnson 
should be contacted at (205) 599-1020 or (205) 934-7110. He 
will be available to answer your questions before, during, and 
after the study.
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16. New Findings: If any significant new findings occur during the course of the 
study including problems that others who have participated have 
experienced in the study, you will be informed of this by one of 
the investigators listed above.
17. How to Learn More About Your Rights as a Reseach Subject:
If you have any questions about your rights as a research subject, 
contact the Baptist Health System Human Research Review 
Board, 800 Montclair Road, Birmingham, AL 35213, telephone 
205/592-5700.
18. Signatures: The study has been discussed with me and all my questions have 
been answered. I may direct additional questions regarding study 
specifics to the investigators. I agree to participate in the study 
described above and acknowledge the investigator’s obligation to 
provide me with a signed copy of the consent form.
Subject Signature Date
Signature of Reader
The study subject has indicated to me that he/she is unable to 
read. I certify that I have read this consent form to the subject 
and explained that by completing the signature line above, the 
subject has agreed to participate.
Date
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Appendix D
Alton Ochsner Medical Foundation Informed Consent
Examination o f a Method for Increasing Adjustment to and Compliance with Nasal 
Continuous Positive Airway Pressure (CPAP) in Persons with Obstructive Sleep Apnea
Syndrome
This study in not sponsored, and is a doctoral dissertation research project.
Principal Investigator: William F. Waters, Ph.D.
Sub-Investigators: Jack A. Johnson, Jr., MA and Mark Hurry, Ph.D.
You have been invited to participate in the clinical research study . Examination of a 
Method for Increasing Adjustment to and Compliance with Nasal Continuous Positive 
Airway Pressure (CPAP) in Persons with Obstructive Sleep Apnea Syndrome.
The doctors at Ochsner study the nature of disease and attempt to develop improved 
methods of diagnosis and treatment. This is called clinical research. To decide whether 
or not you should agree to be part of this research study, you should understand enough 
about its risks and benefits to make an informed judgment. This process is called 
informed consent.
Purpose
The purpose of this study is to examine a method that may help people to adjust better to 
nasal Continuous Positive Airway Pressure (called CPAP) treatment for sleep apnea. 
Sleep apnea is a sleep disorder which means that a person ceases to breathe repeatedly for 
a short periods o f time while asleep. You have been asked to participate in this study 
because  ̂based on a review of your symptoms, your physician has determined that you 
may be at significant risk of having sleep apnea. As part of your sleep study, you might 
receive CPAP treatment if professionals in the sleep laboratory determine that you have 
sleep apnea.
Procedure
You will be spending the night in the sleep laboratory for a diagnostic evaluation, which 
could include a CPAP trial aimed at finding a proper level o f treatment (air pressure) for 
obstructive sleep apnea, a routine procedure for persons who have this sleep disorder. 
CPAP delivers a constant stream of pressured air through your nose, which prevents you 
from stopping breathing during sleep. You may not receive a CPAP trial during the 
course o f the night if you do not have obstructive sleep apnea or if the degree of your 
illness does not warrant CPAP treatment during the same night as your initial diagnostic 
sleep study.
If you agree to participate in this research study, the diagnostic sleep study will occur 
immediately after we have completed the procedures required for this research study.
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Subjects who agree to participate in this study will be randomly assigned to one of two 
groups. This means that you will have a SO/SO chance of being placed in either of these 
two groups. This method is similar to the flip of a coin.
If you are assigned to the first group, you will be asked to wear the CPAP mask with air 
pressure before bedtime while you are not in bed and not attempting to fall asleep.
There will be no change in the way that CPAP is normally used in the Sleep Disorders 
Center, Ochsner Clinic, Baton Rouge. The total time that you will be asked to wear the 
CPAP mask with pressure is approximately 30 minutes, during which time you will 
experience a range of gradually building CPAP pressures that are commonly experienced 
during the course of a sleep study with CPAP. You will experience four pressure settings 
for exactly seven and a half minutes each. The pressure will be increased every seven and 
a half minutes and will increase a total of three times before the trial comes to a 
conclusion. During the time that you are wearing the CPAP mask, you may engage in 
any relaxing activity that you choose, including watching television or reading. Data 
from the sleep study and home CPAP use for the first several weeks you are using CPAP 
(only if your are prescribed CPAP treatment) will be compared against persons receiving 
the routine laboratory procedures.
If you are assigned to the second group, you will be asked to provide some additional 
information in a Sleep Disorders Inventory about your sleep problem in addition to 
receiving the routine clinical care that is currently the community standard of care in 
centers specializing in the diagnosis and treatment of sleep disorders. Data from your 
sleep study and home CPAP use for the first several weeks you are using CPAP (only if 
your are prescribed CPAP treatment) will be compared against those persons who are in 
the first group and are receiving a variation of the normal laboratory procedures.
You will receive written information about CPAP treatment for sleep apnea for 
educational purposes. Your participation will not reduce or modify information that is 
normally gathered during the course o f a sleep study. Finally, the proposed study is not 
an experimental procedure, but rather is an examination of a variation of the CPAP 
procedure that has been designed with the aim of evaluating its potential in making 
adjustment to CPAP easier.
Benefits
This study may benefit you in your adjustment to CPAP and will further scientific 
knowledge in the field of sleep medicine concerning the treatment o f obstructive sleep 
apnea syndrome with CPAP. No direct benefit to you may result from your 
participation in this study.
Risks
One risk is that some persons experience anxiety, which may take the form of 
claustrophobia, while wearing the CPAP mask. If this occurs, alert the investigator who 
will be in the room with you during the procedure. In general, there is only one major 
reason that CPAP should not be used for the treatment of sleep apnea. CPAP should
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not be used in persons who have suffered a very severe head or spinal injury that caused 
leakage of cerebrospinal fluid (the fluid which surrounds and cushions the brain).
Persons who have experienced an injury of this nature are not eligible to participate.
You understand that Louisiana state law requires that participants in all clinical studies 
such as this one be informed that any study (or procedure) may also result in death, brain 
damage, quadripiegia (paralysis in all arms and legs), paraplegia (paralysis of both legs), 
loss of organ, loss of arm or leg, loss of function of organ, loss of function of an arm or 
leg, and disfiguring scars.
Alternative Methods/Treatments
Currently, CPAP is clearly the best treatment for sleep apnea for most people. You do 
not have to participate in this study in order to receive CPAP. Your doctor will also 
discuss other treatment options with you, which range from weight loss to palatal 
surgery.
The current study is not a treatment for sleep apnea, but rather an examination of a 
method of helping people adjust to CPAP after they experience CPAP in the laboratory 
during sleep to prevent sleep apnea.
Payment for Participations and/or Reimbursement of Expenses
You will not be paid to participate in this study, and there will be no cost to you for 
participating.
Additional Costs
There are no known additional or anticipated costs for participating in the study. 
Compensation for Injury
You understand that in the event of related injury from the research procedures, medical 
treatment, including hospitalization, if necessary for injuries or illness, is available. This 
medical treatment and/or hospitalization not provided free of charge. No provision for 
monetary compensation has been made in the event of an injury resulting from the 
research.
Confidentiality
The confidentiality of your records will be maintained to the extent consistent with the 
law. Governmental agencies, such as the Food and Drug Administration, may review and 
copy your records to ensure compliance with regulations and protocols. Additionally, the 
sponsor and Ochsner authorized officials may review your records to ensure compliance. 
You will not be identified in any reports or publications resulting from the study.
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Contact Information
You understand that should you have any questions about the study or suffer any injury 
that you feel may be related to the study, upi should contact the Responsible 
Investigator William F. Waters, Ph.D. or his associate, Jack A. Johnson, Jr., MA by 
calling (225) 761-5852. You also understand that you may take any problem or any 
question concerning your rights to the Office of Research Administration, Fifth Floor, 
Brent House, Telephone (504) 842-3562.
Safeguards
Whereas no assurance can be made concerning the results that may be obtained 
(since results from a clinical research study cannot be predicted), your 
physician, acting as Responsible Investigator, will take every precaution 
consistent with the best medical practice;
By signing this consent form you have not waived any of your legal rights or 
released this institution from liability for negligence.
Participation in this study is voluntary. You may revoke your consent and 
withdraw from this study at any time without any penalty or loss o f benefits to 
which you are otherwise entitled;
You have disclosed to your doctors all of your past and present diseases and 
allergies of which you are aware and all drugs and medications which you are 
presently using.
Additional Information
If any significant new findings occur during the course of the study, including problems 
that others who have participated have experienced in the study, you will be informed 
of this by one of the investigators above. Although not anticipated, the investigators 
reserve the right to eliminate any subject from participating fiirther regardless of a 
subject’s consent. Circumstances under which this might occur would include 
terminating the CPAP trial early if continuation of the trial would prevent you from 
starting your sleep study on time during the night o f your participation. There are no 
consequences of any kind for a subject who wishes to voluntarily withdraw from the 
study. The procedure for withdrawing from the study is to 1) inform the investigator 
during the course of your participation during the experiment or 2) to contact one of the 
investigators at the telephone number listed above if you wish to withdraw at a later 
time.
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Statement of Voluntary Agreement to Participate
The procedure(s) involved, expected duration of participation, alternative 
methods/treatments, and possible benefits, discomforts, risks, and adverse effects have 
been explained to me in language I understand as set forth above by Dr. William F. 
Waters or his representative, Jack A. Johnson, Jr., MA I have been given the time to ask 
questions, which have been answered to my satisfaction. I have been given a copy of this 







Physician (Responsible Investigator) Date
94
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Appendix E
Sleep Disorders Inventory
William F Waters, P h D , ABPP, BCSS 
Director, Ochsner Clinic of Baton Rouge, Sleep Disorders Center
and
Professor, Department of Psychology, Louisiana State University 
Please provide the following information:
Name: __________________________________Clinic Number____________________
Date: ____________ Age:_________Birth Date:_____________Weight:___________
Height:  BMI ________
Instructions: The following questions will help us understand any sleep problems you 
may have. Please answer all of the questions to the best of your ability. For some 
questions, you should circle YES if the item is true for you or NO if the item does not 
apply to you. For other questions, a space is provided for you to write a number, such as 
how many minutes it takes you to fall asleep. For all questions, give an answer that is the 
closest to the truth as you know it. For some questions, you may have to ask someone 
who has seen you sleep; if no one has seen you sleep, write DK (don’t know).
1. What is your primary sleep problem?
How long have you had that problem? No. Years; No. Months;__No. Weeks
2. At what time do you usually turn out the lights to go to sleep?........................ ..............
At what time do you usually wake up for the next day?..................................................
3. How many minutes does it usually take you to fall asleep?............................................
4. How many nights a week do you get 9 or more hours sleep?.......................... ...............
How many nights a week do you get 8 hours sleep?........................................ ..............
How many nights a week do you get 7 hours sleep?........................................ ..............
How many nights a week do you get 6 hours sleep?......................................... ..............
How many nights a week do you get 5 or less hours sleep?............................ ..............
5. Do you take 30 minutes or more to fall asleep, more than once a week? YES NO
If YES: How many nights does this happen each week?................................ ...............
On nights when you have this problem how many minutes does it take you to fall
asleep?................................................................................................................ ...............
On nights when you have this problem, how many hours do you sleep? ..............
6. Do you wake up during the night and take 20 minutes or more to regain sleep, more 
than once a week?.............................................................................................YES NO
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If YES: How many nights does this happen each week?................................ ...............
On average, how many times does this happen each night? ..............
How many minutes does it take you to fall back asleep each time? . _______
On nights when you have this problem, how many hours do you sleep?_____
7. Do you often wake up in the morning before your scheduled wake time, and cannot
go back to sleep? YES NO
If YES: How many nights each week do you have this problem?................... ..............
On nights when you have this problem, how many hours do you sleep?_____
8. Do you often fall asleep at inappropriate times or places during the day because you 
are not getting
enough sleep?.....................................................................................................YES NO
9. Do you often have trouble functioning during the day because you are not getting 
enough sleep? YES NO
10. On nights when you do get a full night’s sleep, do you stiU:
• Have trouble waking up, or wake up feeling unrefreshed? YES NO
• Fall asleep involuntarily during the day, but only when somewhat unstimulated?. .
 YES NO
If YES, check each example that applies to you: While watching TV ,
while reading a book , while a passenger in a car , while in a traffic
jam
• Fall asleep involuntarily during the day, even when doing something important or
stimulating? YES NO
If YES, check each example that applies to you: While driving_____ , while
doing your work , while talking to others .
•  Have trouble functioning during the day?.....................................................YES NO
11. Do you ever sleep 12 or more hours and still wake up unrefreshed?................ YES NO
If YES, do you still need to nap during the day? YES NO
If YES, how many times a month does this occur?......................................... ...............
12. How many nights per month do you:
 Snore loudly and persistently
 Thrash about while asleep (but are not dreaming)
 Gasp or snort while asleep
  Stop breathing while asleep or wake up in the night and feel unable to breathe
 How many mornings a month do you awaken with a headache?
13. Does it often take you longer to fall asleep because your legs feel restless or odd in
bed?...................................................................................................................... YES NO
If YES: Does moving your legs in bed, or getting up and moving around help you
fall asleep?............................................................................................................YES NO
How many nights per month do your legs feel this way?................................ ................
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14. Do you often wake from a sound sleep repeatedly because your legs jerk?.. YES NO 
If YES . Are your leg movements frequent and regular? YES NO
How many nights per month does this happen?................................ ...............
15. Have sleep attacks in which you suddenly and uncontrollably fall asleep? . ..YES NO 
If YES: How many minutes do you sleep (nap) when you have such an attack?____
Do you awaken from your nap feeling refreshed? YES NO
How many times per month does this happen?................................ ................
16. When you are startled, emotional, excited or happy do you often experience extreme 
weakness (for example, in your legs) or drop things? YES NO
17. When you are startled, emotional, or excited do you often collapse or fall?.. YES NO 
If YES: Are you still aware of your surroundings? YES NO
18. As you fall asleep or wake up, do you often see things that are not there?.. YES NO 
If YES: Are the things you see very clear and realistic? YES NO
How many times each month does this happen?............................................
19. As you fall asleep or wake up, are you often unable to move (paralyzed)? .. YES NO 
If YES: How many times each month?...........................................................................
18. How many nights have nightmares awakened you in the last month? ..............
If ANY: How intense are they? (l=Mild, 2=Frightening, 3=Terrifying) . . . . _______
19. Do you often move violently during your sleep while dreaming, and sometimes even
hurt yourself or your partner by accident or fall out of bed?  YES NO
If YES: How many times in the last month has this happened?..................... ...............
20. Do you often wake up from a deep sleep sweating, your heart beating fast or
pounding, with a feeling of fear but with no memory of a dream? YES NO
If YES: How many times in the last month has this happened?.................... ...............
How intense is this experience? (l=Mild, 2=Frightening, 3=Terrifying)_____
Does this ever happen during the day?................................................ YES NO
21. Do you often grind your teeth in your sleep?.................................................... YES NO
22. How many times each night do you wake up specifically to use the bathroom?______
23. How many nights each week do you wake up with indigestion or heartburn?._______
24. Do you often eat your last meal or a large snack within 2 hours o f bedtime? YES NO
25. Do you often exercise vigorously within an hour of bedtime?.........................YES NO
26. How many nights each month do you use alcohol within 2 hours of bedtime._______
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27. How many nights each month do you use alcohol to help you fall asleep?.. . . ____
28. How many caffeinated beverages do you drink in a day?................................. .........
29. How many days a week do you drink caffeinated beverages after 7 p.m.?. . . ____
30. How often is your sleep problem caused or made worse by physical discomfort or
pain? (check one): Never  Rarely  Sometimes Often_____
Most or All of the Time
31. Do you ever work night shifts (any 8-12 hour shift starting after 6 pm)? YES NO
If YES: How many nights per month? .......................................................................
32. Do you often work at home after 8 pm? YES NO
If YES: How many nights per week?...........................................................................
33. Do you deliberately sleep less in order to do other things?.............................. YES NO
If YES: How many nights per week?.............................................................. ................
How many hours per night?............................................................... ...............
34. On weekends or your days off, do you often sleep more than 1 hour later than your 
usual wake up time?........................................................................................... YES NO
35. Do you often go to bed earlier to make up for lost or unrefreshing sleep?. . .  YES NO
36. Do you often wake up later to make up for lost or unrefreshing sleep?........... YES NO
37. Do you take naps?............................................................................................. YES NO
If YES: How many times each week do you take naps?.................................................
How many minutes are your naps, on average?...............................................
Do you awaken from your naps refreshed?........................................YES NO
38. Do you often lose sleep because your bed partner disturbs you at night? YES NO
39. Is your sleep often disturbed by environmental factors, such as traffic, neighbors or 
family members?................................................................................................ YES NO
40. Do you often lose sleep because your bedroom is not dark enough at night? YES NO
41. Do you often lose sleep because your bedroom temperature is not comfortable enough 
at night?...............................................................................................................YES NO
42. Do you usually sleep better when you sleep away from home?........................ YES NO
43..When you try to sleep, does worrying or problem solving often keep you awake?.. . .  
........................................................................................................................... YES NO
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44. Do you often worry, in bed, about getting enough sleep to function the next day? . . . .  
...........................................................................................................................YES NO
45. Do you often get frustrated and angry, in bed, about not getting to sleep?... YES NO
46. Do you worry too much in general?.................................................................YES NO
47. Have you been under noteworthy stress recently?...........................................YES NO
48. Check if you are currently diagnosed with:___ depression____ an anxiety disorder
49. Have you recently taken any prescription or over-the-counter medication for sleep
problems?......................................................................................................... YES NO
If YES: How many nights a week do you usually take this medication? . . .  _______
How many months have you been taking this medication? ..............
50. Do you take any medications that contain caffeine or other stimulants, such as allergy
medications, nasal decongestants, or pain killers?............................................YES NO
If YES: How many minutes or hours before trying to sleep do you take them?______
51. Please list all prescription and over-the-counter medications you are now taking, and 
what each is for:
MEDICATION CONDITION MEDICATION CONDITION
52. Please list any medications you have recently stopped taking, and what each was for:
MEDICATION CONDITION MEDICATION CONDITION
You may write any additional information that you think could be helpful in the space 
below, or on the back of this page:
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Appendix F
Correlation Coefficients for PSG Variables: Split-Night




T s i T 41W* -.17 -.25 .49” .15
SE ___ -.52" -.02 .32* -.45" -.53"
% l _______ -.19 -.25 ..74“ ..62"
%SWS _______ -.02 -.11 -.19





Note. * significant at .05 level, 2-tailed, ** significant at .01 level, 2-tailed.
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Appendix G
Correlation Coefficients for PSG Variables: Full-Night
Variable SOL SE %1 %sws REM STA No.
Awake
SOL -.59 .42" -.23 -.53* .39" .21
SE - -.51“ .18 .44 -.33“
••001*
% l -  . -31* -.56* .69“ 67”
%sws .28 -.14 -.33*





Note. * significant at .05 level, 2-tailed, ** significant at .01 level, 2-tailed.
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Appendix H
Correlation Coefficients Relevant to an Examination of CPAP Use
Variable Gender BMI A+HI Accept CPAP
Use
Titration
Gender — -.01 -.36" .06 -.33“ .54"
BM1 — .21 .01 .16 -.14
A+Hl — .11 .22 -.40"





Note. * two-tailed significance of p < .05, ** two-tailed significance of p < .01,t  cannot 
be calculated because Use is dependent upon Acceptance of CPAP.
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Vita
Jack A. Johnson, Jr. was born in Atlanta, Georgia and grew up in a suburb 
Knoxville, Tennessee. He lived in Knoxville until he was 24 years old and spent too 
much time playing guitar and Super Nintendo with friends from college. Jack moved to 
Baton Rouge in the fall of 1994 to begin his graduate studies in psychology at the 
Louisiana State University and Agricultural and Mechanical College. He also spent two 
long and boring years in Birmingham, Alabama where he and his wife, DeAnn M. 
Johnson, completed psychology internships at the University of Alabama at Birmingham 
psychology consortium. As you probably guessed because he is from the southern United 
States, Jack is a rabid college football fan and follows the Tennessee Volunteers and the 
Tigers almost every Saturday from September through the first week of January. 
Additionally, Jack and his wife enjoy the New Orleans Saints’ games on Sundays. You 
might be surprised to know that Jack’s true passion in life is not psychology but is history. 
Jack is particularly interested in the sacrifice and courage of those who fought in World 
War II. American history is another area of great interest for Jack, and he plans to spend 
much of his free time reading about noteworthy events in history. Also, Jack has 
aspirations to write about history, and has plans to explore writing a book about men from 
Louisiana who served in the United States Merchant Marines during World War II.
Music is another area of interest for Jack, and he wrote the passage you are now reading 
while listening to the Red Hot Chili Peppers’ Blood Sugar Sex Magic. Aerosmith, 
AC/DC, and Led Zeppelin are long time favorites of his and helped ease the pain of 
completing graduate school. Finally, Jack’s life history would not be complete without 
mentioning his loyal and loving cat Claire, known to her friends as Swiggums. She
particularly likes spending quality time with her family, and is generally one cool cat.
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